Désiré Collen

Q: What Schools Are Affiliated With Désiré Collen

Désiré Collen is affiliated with the following schools: Monash University, Ghent University, McGill University, University College London, University of Tokyo, KU Leuven, University of Michigan, University of Notre Dame, Umeå University, University of Toronto, Massachusetts General Hospital

Désiré Collen's AcademicInfluence.com Rankings

Désiré Collen

Chemistry

#480

World Rank

#879

Historical Rank

Organic Chemistry

#51

World Rank

#74

Historical Rank

chemistry Degrees

Désiré Collen

Philosophy

#1728

World Rank

#3086

Historical Rank

Logic

#294

World Rank

#598

Historical Rank

philosophy Degrees

Download Badge

Chemistry
Philosophy

Why Is Désiré Collen Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Désiré, Baron Collen is a Belgian physician, chemist, biotechnology entrepreneur and life science investor. He made several discoveries in thrombosis, haemostasis and vascular biology in many of which serendipity played a significant role. His main achievement has been his role in the development of tissue-type plasminogen activator from a laboratory concept to a life-saving drug for dissolving blood clots causing acute myocardial infarction or acute ischemic stroke. Recombinant t-PA was produced and marketed by Genentech Inc as Activase and by Boehringer Ingelheim GmbH as Actilyse, and is considered biotechnology's first life saving drug.

(See a Problem?)

Désiré Collen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele (1996) (4330)
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis (1998) (2183)
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions (2001) (1669)
Targeted Deficiency or Cytosolic Truncation of the VE-cadherin Gene in Mice Impairs VEGF-Mediated Endothelial Survival and Angiogenesis (1999) (1346)
Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. (1982) (1286)
Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli (1983) (1118)
Physiological consequences of loss of plasminogen activator gene function in mice (1994) (1107)
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 (2002) (1099)
Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration (2001) (1032)
On the Regulation and Control of Fibrinolysis (1980) (1023)
Molecular mechanisms of blood vessel growth. (2001) (1006)
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death (2003) (881)
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure (1999) (843)
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 (2003) (782)
Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels (2007) (778)
Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. (1981) (761)
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization (1998) (728)
Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188 (1999) (725)
Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. (1998) (723)
Role of tissue factor in embryonic blood vessel development (1996) (721)
Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation (1997) (698)
RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator (1985) (662)
Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. (1988) (593)
Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis (vol 394, pg 485, 1998) (1998) (579)
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. (2002) (556)
Duodenal calcium absorption in vitamin D receptor–knockout mice: Functional and molecular aspects (2001) (547)
Circulating Oxidized LDL Is a Useful Marker for Identifying Patients With Coronary Artery Disease (2001) (546)
Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice (2002) (523)
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS (2005) (516)
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. (1991) (475)
Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice (2002) (466)
Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. (1986) (463)
Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). (1988) (455)
Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis (2001) (452)
The Plasminogen (Fibrinolytic) System (1999) (446)
Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188 (2000) (441)
Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. (1988) (437)
Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. (1985) (423)
Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. (1993) (417)
Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. (1984) (389)
Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. (1982) (381)
Deficient t-PA Release and Elevated PA Inhibitor Levels in Patients with Spontaneous or Recurrent Deep Venous Thrombosis (1987) (376)
Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. (1995) (376)
Molecular mechanism of physiological fibrinolysis (1978) (375)
Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. (1989) (368)
Basic and Clinical Aspects of Fibrinolysis and Thrombolysis (1991) (365)
Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. (2004) (364)
Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. (1984) (355)
Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. (1993) (351)
Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. (1976) (341)
Transcription Factor Hepatocyte Nuclear Factor 6 Regulates Pancreatic Endocrine Cell Differentiation and Controls Expression of the Proendocrine Gene ngn3 (2000) (338)
The Plasminogen Activator Inhibitor PAI-1 Controls In Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin: Implications for Antiangiogenic Strategies (2001) (337)
Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with late-phase long-term potentiation in both Schaffer collateral and mossy fiber pathways. (1996) (337)
The Lectin-like Domain of Thrombomodulin Confers Protection from Neutrophil-mediated Tissue Damage by Suppressing Adhesion Molecule Expression via Nuclear Factor κB and Mitogen-activated Protein Kinase Pathways (2002) (333)
Insulin Stimulates the Synthesis of Plasminogen Activator Inhibitor 1 by the Human Hepatocellular Cell Line Hep G2 (1988) (326)
Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. (1986) (324)
Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. (1991) (322)
Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. (1999) (316)
Plasminogen activator inhibitor in the blood of patients with coronary artery disease. (1985) (315)
Loss of Matrix Metalloproteinase-9 or Matrix Metalloproteinase-12 Protects Apolipoprotein E–Deficient Mice Against Atherosclerotic Media Destruction but Differentially Affects Plaque Growth (2004) (308)
VEGF: A modifier of the del22q11 (DiGeorge) syndrome? (2003) (307)
Tissue‐Type Plasminogen Activator Antigen and Plasminogen Activator Inhibitor in Diabetes Mellitus (1988) (301)
Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. (2003) (299)
Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. (1996) (274)
Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity. (2002) (274)
Molecular Basis of Angiogenesis: Role of VEGF and VE‐Cadherin (2000) (273)
Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. (1997) (269)
Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. (1984) (265)
Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease (2010) (265)
Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. (2005) (263)
Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. (1983) (257)
Clot-selective coronary thrombolysis with tissue-type plasminogen activator. (1983) (253)
Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. (1998) (252)
Assay of Human Tissue-Type Plasminogen Activator (t-PA) with an Enzyme-Linked Immunosorbent Assay (ELISA) Based on Three Murine Monoclonal Antibodies to t-PA (1985) (251)
On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen. (1979) (249)
Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. (1998) (249)
Persistence of Atherosclerotic Plaque but Reduced Aneurysm Formation in Mice With Stromelysin-1 (MMP-3) Gene Inactivation (2001) (249)
A mouse model for Zellweger syndrome (1997) (248)
Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome (2001) (247)
Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. (1980) (246)
Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. (1997) (243)
Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. (1988) (239)
Generation and characterization of urokinase receptor-deficient mice. (1996) (236)
Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus (1981) (236)
A genetic Xenopus laevis tadpole model to study lymphangiogenesis (2005) (236)
Studies on the Specific Fibrinolytic Effect of Human Extrinsic (Tissue-Type) Plasminogen Activator in Human Blood and in Various Animal Species in Vitro (1981) (235)
Mice lacking factor VII develop normally but suffer fatal perinatal bleeding (1997) (232)
DOUBLE-BLIND RANDOMISED TRIAL OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS PLACEBO IN ACUTE MYOCARDIAL INFARCTION (1985) (231)
Plasma Plasminogen Activator Inhibitor‐1 in Angina Pectoris: Influence of Plasma Insulin and Acute‐phase Response (1989) (231)
Modulation of angiogenesis during adipose tissue development in murine models of obesity. (2005) (226)
Cardiomyocyte-Specific Overexpression of Nitric Oxide Synthase 3 Improves Left Ventricular Performance and Reduces Compensatory Hypertrophy After Myocardial Infarction (2004) (225)
Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. (1998) (223)
Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. (1995) (221)
Vascular wound healing and neointima formation induced by perivascular electric injury in mice. (1997) (221)
Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. (1988) (221)
Studies on the mechanism of the antifibrinolytic action of tranexamic acid. (1981) (219)
Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine. (1987) (217)
Impaired arterial neointima formation in mice with disruption of the plasminogen gene. (1997) (211)
Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. (1999) (211)
Reduced Atherosclerotic Plaque but Enhanced Aneurysm Formation in Mice With Inactivation of the Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Gene (2002) (210)
Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. (1990) (210)
Oxidized lipoproteins in atherosclerosis and thrombosis (1994) (208)
Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. (1998) (204)
Plasminogen and Plasminogen Activators Protect against Renal Injury in Crescentic Glomerulonephritis (1997) (202)
Inactivation of the Peroxisomal Multifunctional Protein-2 in Mice Impedes the Degradation of Not Only 2-Methyl-branched Fatty Acids and Bile Acid Intermediates but Also of Very Long Chain Fatty Acids* (2000) (202)
Adenovirus-Mediated Gene Transfer of Human Platelet-Activating Factor–Acetylhydrolase Prevents Injury-Induced Neointima Formation and Reduces Spontaneous Atherosclerosis in Apolipoprotein E–Deficient Mice (2001) (199)
Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. (1998) (197)
Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). (1998) (196)
On the mechanism of fibrin-specific plasminogen activation by staphylokinase. (1991) (195)
Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. (1983) (194)
Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. (1999) (193)
Turnover of Human Extrinsic (Tissue-Type) Plasminogen Activator in Rabbits (1981) (193)
Genetic evidence for a tumor suppressor role of HIF-2alpha. (2005) (192)
Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. (1990) (191)
Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. (1984) (189)
Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. (1998) (189)
Cardia bifida, defective heart development and abnormal neural crest migration in embryos lacking hypoxia-inducible factor-1alpha. (2003) (188)
Correlation between Oxidized Low Density Lipoproteins and von Willebrand Factor in Chronic Renal Failure (1996) (187)
Activation of plasminogen by pro-urokinase. I. Mechanism. (1986) (182)
Mechanisms of physiological fibrinolysis. (1995) (182)
Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. (1998) (180)
Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. (2000) (178)
Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator? (1990) (177)
Comparison of the Relative Fibrinogenolytic, Fibrinolytic and Thrombolytic Properties of Tissue Plasminogen Activator and Urokinase in Vitro (1981) (177)
Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. (2002) (175)
Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. (1986) (173)
Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent (1998) (172)
Failure of Thrombus to Resolve in Urokinase-Type Plasminogen Activator Gene-Knockout Mice: Rescue by Normal Bone Marrow-Derived Cells (2003) (172)
A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group. (1995) (166)
Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration (1977) (164)
Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis. (1982) (163)
Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. (1985) (162)
Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. (2005) (160)
Strategies for the Improvement of Thrombolytic Agents (1991) (160)
Blood Coagulation Factor X Deficiency Causes Partial Embryonic Lethality and Fatal Neonatal Bleeding in Mice (2000) (160)
Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. (2005) (159)
HDLassociated PAF‐AH reduces endothelial adhesiveness in apoE−/− mice (2000) (156)
Circulating activated platelets assist THP-1 monocytoid/endothelial cell interaction under shear stress. (1999) (156)
Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. (2000) (156)
Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats. (1996) (155)
Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay. (1983) (153)
Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – I. Fibrinolytic and Fibrinogenolytic Properties in Human Plasma In Vitro of Urokinases Obtained from Human Urine or by Recombinant DNA Technology (1984) (151)
Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. (1984) (149)
Placental Growth Factor Promotes Atherosclerotic Intimal Thickening and Macrophage Accumulation (2005) (149)
Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator. (1984) (148)
Thrombolytic therapy in the eighties. (1986) (147)
Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator. (1992) (143)
A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris. (1987) (142)
Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin). (1987) (142)
Receptor-independent Role of Urokinase-Type Plasminogen Activator in Pericellular Plasmin and Matrix Metalloproteinase Proteolysis during Vascular Wound Healing in Mice (1998) (141)
Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential? (1994) (140)
SPECIFIC LYSIS OF AN ILIOFEMORAL THROMBUS BY ADMINISTRATION OF EXTRINSIC (TISSUE-TYPE) PLASMINOGEN ACTIVATOR (1981) (140)
Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. (2000) (139)
Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3. (1987) (138)
Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. (1990) (138)
Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis. (1998) (138)
Activation of Plasminogen by Pro-urokinase (1986) (136)
The lectin‐like domain of thrombomodulin interferes with complement activation and protects against arthritis (2006) (135)
Molecular analysis of blood vessel formation and disease. (1997) (134)
Matrix Metalloproteinase Inhibition Impairs Adipose Tissue Development in Mice (2002) (134)
Lack of Plasminogen Activator Inhibitor-1 Promotes Growth and Abnormal Matrix Remodeling of Advanced Atherosclerotic Plaques in Apolipoprotein E–Deficient Mice (2002) (134)
Tissue‐type plasminogen activator: a historical perspective and personal account (2004) (134)
Matrix Metalloproteinase System Deficiencies and Matrix Degradation (1999) (134)
Basic and clinical aspects of fibrinolysis and thrombolysis. (1991) (132)
Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. (1998) (131)
Plasminogen receptors, urokinase receptors, and their modulation on human endothelial cells. (1988) (129)
Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase. (1984) (129)
Insights in Vessel Development and Vascular Disorders Using Targeted Inactivation and Transfer of Vascular Endothelial Growth Factor, the Tissue Factor Receptor, and the Plasminogen System (1997) (129)
Malondialdehyde-modified LDL as a marker of acute coronary syndromes. (1999) (128)
Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complex. (1986) (128)
Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody. (1990) (126)
Thrombosis and atherosclerosis (1997) (125)
Evidence for localization of polymerization sites in fibrinogen. (1974) (125)
Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy. (1993) (125)
Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction. (1986) (124)
Effect of Retraction on the Lysis of Human Clots with Fibrin Specific and Non-Fibrin Specific Plasminogen Activators (1989) (123)
Immunoassay of Murine t-PA, u-PA and PAI-1 Using Monoclonal Antibodies Raised in Gene-inactivated Mice (1995) (121)
Ovulation efficiency is reduced in mice that lack plasminogen activator gene function: functional redundancy among physiological plasminogen activators. (1995) (120)
Purification of Human Tissue-Type Plasminogen Activator in Centigram Quantities from Human Melanoma Cell Culture Fluid and Its Conditioning for Use In Vivo (1982) (119)
Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. (1999) (119)
Differential effects of progenitor cell populations on left ventricular remodeling and myocardial neovascularization after myocardial infarction. (2010) (118)
Endothelium in hemostasis and thrombosis. (1997) (117)
Activation of plasminogen by pro-urokinase. II. Kinetics. (1986) (117)
Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate. (1987) (117)
Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator. (1988) (116)
Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. (1990) (115)
Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). (1992) (115)
Improved Generation of Germline‐Competent Embryonic Stem Cell Lines from Inbred Mouse Strains (2003) (115)
Stromelysin‐1 (MMP‐3) is critical for intracranial bleeding after t‐PA treatment of stroke in mice (2007) (115)
Vascular development and disorders: molecular analysis and pathogenic insights. (1998) (114)
Cytochrome P450 Epoxygenase Gene Function in Hypoxic Pulmonary Vasoconstriction and Pulmonary Vascular Remodeling (2006) (113)
Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158. (1987) (113)
Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease. (2000) (112)
Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction. (1986) (111)
Synergism of thrombolytic agents in vivo. (1986) (111)
Reduced transplant arteriosclerosis in plasminogen-deficient mice. (1998) (110)
On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin. (1978) (109)
Interaction of AP-1-, AP-2-, and Sp1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response. (1992) (108)
The presence and release of alpha 2-antiplasmin from human platelets. (1981) (108)
A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits. (1985) (108)
A Novel Role for Vascular Endothelial Growth Factor as an Autocrine Survival Factor for Embryonic Stem Cells during Hypoxia* (2005) (107)
Interaction of plasminogen activators and inhibitors with plasminogen and fibrin. (1982) (107)
High Yield Production and Purification of Recombinant Staphylokinase for Thrombolytic Therapy (1994) (107)
Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator. (1989) (107)
Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. (1987) (106)
Ham-Wasserman lecture: role of the plasminogen system in fibrin-homeostasis and tissue remodeling. (2001) (106)
Hypoxia-inducible Factor-2α (HIF-2α) Is Involved in the Apoptotic Response to Hypoglycemia but Not to Hypoxia* (2001) (105)
Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice. (2002) (105)
Kinetics of the reactions between streptokinase, plasmin and alpha 2-antiplasmin. (1979) (104)
Fibrinolytic Response and Fibrin Fragment D-Dimer Levels in Patients with Deep Vein Thrombosis (1987) (104)
Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator. (1986) (104)
Replacement of the Muscle-Specific Sarcoplasmic Reticulum Ca2+-ATPase Isoform SERCA2a by the Nonmuscle SERCA2b Homologue Causes Mild Concentric Hypertrophy and Impairs Contraction-Relaxation of the Heart (2001) (104)
Nutritionally Induced Obesity Is Attenuated in Transgenic Mice Overexpressing Plasminogen Activator Inhibitor-1 (2003) (101)
The tissue-type plasminogen activator story. (2009) (101)
Characterization of the murine plasma fibrinolytic system. (1994) (101)
Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. (2001) (101)
Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu). (1990) (101)
Metabolism of fibrinogen in cirrhosis of the liver. (1971) (100)
Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – III. Thrombolytic Properties of Natural and Recombinant Urokinase in Rabbits with Experimental Jugular Vein Thrombosis (1984) (100)
Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. (2002) (100)
Detection of coronary artery reperfusion with creatine kinase-MB determinations during thrombolytic therapy: correlation with acute angiography. (1988) (99)
Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction (1995) (99)
Regulation of Gelatinase Activity in Mice with Targeted Inactivation of Components of the Plasminogen/Plasmin System (1998) (99)
On the mechanism of the activation of human plasminogen by recombinant staphylokinase. (1993) (98)
Purification and characterization of a novel inhibitor of urokinase from human urine. Quantitation and preliminary characterization in plasma. (1986) (98)
Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. (1988) (97)
Kistrin, a Polypeptide Platelet GPIIb/IIIa Receptor Antagonist, Enhances and Sustains Coronary Arterial Thrombolysis With Recombinant Tissue‐Type Plasminogen Activator in a Canine Preparation (1991) (97)
Neutralization of Human Extrinsic (Tissue-Type) Plasminogen Activator in Human Plasma: No Evidence for a Specific Inhibitor (1981) (97)
Plasma Fibrinopeptide A Levels in Patients With Acute Myocardial Infarction Treated With Alteplase: Correlation With Concomitant Heparin, Coronary Artery Patency, and Recurrent Ischemia (1992) (96)
LDL hypercholesterolemia is associated with accumulation of oxidized LDL, atherosclerotic plaque growth, and compensatory vessel enlargement in coronary arteries of miniature pigs. (1998) (96)
Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice. (1997) (95)
Fibrin-selective thrombolytic therapy for acute myocardial infarction. (1996) (94)
correction: Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis (1998) (94)
Predictive value of increased plasma levels of fibronectin in gestational hypertension (1989) (93)
Molecular Basis of Fibrinolysis, as Relevant for Thrombolytic Therapy (1995) (93)
Role of Gas6 in erythropoiesis and anemia in mice. (2008) (92)
Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation. (2003) (91)
Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents. (1986) (90)
The fibrinolytic system in man. (1986) (90)
Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling. (1996) (90)
Fibrinolysis and Coagulation in Patients with Infectious Disease and Sepsis (1991) (90)
Loss of placental growth factor protects mice against vascular permeability in pathological conditions. (2002) (90)
Intravascular coagulation in liver disease. (1974) (90)
Purification and characterization of single-chain urokinase-type plasminogen activator from human cell cultures. (1986) (89)
Tissue inhibitor of matrix metalloproteinases-1 impairs arterial neointima formation after vascular injury in mice. (1999) (88)
An Enzyme-Linked Immunosorbent Assay (ELISA) for the Measurement of Plasmin-α2-Antiplasmin Complex in Human Plasma - Application to the Detection of In Vivo Activation of the Fibrinolytic System (1986) (88)
Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model. (2002) (88)
Sustained Endothelial Progenitor Cell Dysfunction After Chronic Hypoxia‐Induced Pulmonary Hypertension (2008) (87)
Issue Editorial Focus : Issue Editorial Focus (2005) (87)
Complexes between tissue-type plasminogen activator and proteinase inhibitors in human plasma, identified with an immunoradiometric assay. (1983) (87)
Lack of endothelial cell survivin causes embryonic defects in angiogenesis, cardiogenesis, and neural tube closure. (2007) (86)
Recombinant human microplasmin: production and potential therapeutic properties (2003) (85)
Measurement of Urokinase-Type Plasminogen Activator (u-PA) with an Enzyme-Linked Immunosorbent Assay (ELISA) Based on Three Murine Monoclonal Antibodies (1986) (85)
A monoclonal antibody specific for Lys-plasminogen. Application to the study of the activation pathways of plasminogen in vivo. (1985) (85)
In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. (1990) (85)
Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae (2007) (84)
Comparative Thrombolytic Properties of Tissue-Type Plasminogen Activator and of a Plasminogen Activator Inhibitor-1 -Resistant Glycosylation Variant, in a Combined Arterial and Venous Thrombosis Model in the Dog (1994) (84)
Inhibition of plasmin by normal and antiplasmin-depleted human plasma. (1976) (83)
Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3). (1998) (83)
Involvement of heparin chain length in the heparin-catalyzed inhibition of thrombin by antithrombin III. (1984) (83)
Biological Effects of Disruption of the Tissue‐Type Plasminogen Activator, Urokinase‐Type Plasminogen Activator, and Plasminogen Activator Inhibitor‐1 Genes in Mice a (1994) (82)
The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro. (1989) (82)
Human tissue-type plasminogen activator: from the laboratory to the bedside. (1985) (81)
Molecular mechanisms of fibrinolysis and their application to fibrin‐specific thrombolytic therapy (1987) (81)
Deficiency of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) impairs nutritionally induced obesity in mice (2003) (79)
Functional Interactions between Sp1 or Sp3 and the Helicase-like Transcription Factor Mediate Basal Expression from the Human Plasminogen Activator Inhibitor-1 Gene* (1999) (78)
Congenital and acquired deficiencies of components of the fibrinolytic system and their relation to bleeding or thrombosis (1989) (78)
Dysfibrinogenemia (Fibrinogen Dusard) Associated with Impaired Fibrin-Enhanced Plasminogen Activation (1984) (78)
Gene Targeting and Gene Transfer Studies of the Biological Role of the Plasminogen/Plasmin System (1995) (77)
Alpha 2-antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity. (1987) (77)
Fibrinolysis for acute myocardial infarction: the future is here and now. (2003) (77)
Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis. (1986) (77)
Influence of protein C activation on blood coagulation and fibrinolysis in squirrel monkeys. (1984) (76)
On the role of coagulation and fibrinolysis in atherosclerosis. (1992) (76)
Systemic thrombolytic therapy of acute myocardial infarction? (1983) (76)
Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – II. Turnover of Natural and Recombinant Urokinase in Rabbits and Squirrel Monkeys (1984) (76)
Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator. (1987) (76)
Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction. (1987) (75)
Differential Role of Components of the Fibrinolytic System in the Formation and Removal of Thrombus Induced by Endothelial Injury (1999) (75)
Enhanced nutritionally induced adipose tissue development in mice with stromelysin-1 gene inactivation (2003) (75)
Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase. (1995) (74)
Comparative Immunogenicit and Thrombolytic Properties Toward Arterial and Venous Thrombi of Streptokinase and Recombinant Staphylokinase in Baboons (1993) (74)
A functional assay of protein C in human plasma. (1984) (73)
Aerosol Gene Transfer With Inducible Nitric Oxide Synthase Reduces Hypoxic Pulmonary Hypertension and Pulmonary Vascular Remodeling in Rats (2000) (72)
Overexpression of a Constitutively Active Protein Kinase G Mutant Reduces Neointima Formation and In-Stent Restenosis (2002) (71)
Effect of matrix metalloproteinase inhibition on adipose tissue development. (2005) (71)
The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: Insights from genetic studies (2000) (71)
Coronary thrombolysis in dogs with intravenously administered human pro-urokinase. (1985) (70)
Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector (2002) (70)
Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates. (1985) (70)
Soluble Guanylate Cyclase-&agr;1 Deficiency Selectively Inhibits the Pulmonary Vasodilator Response to Nitric Oxide and Increases the Pulmonary Vascular Remodeling Response to Chronic Hypoxia (2007) (70)
Pharmacokinetics and Effects on Fibrinolytic and Coagulation Parameters of Two Doses of Recombinant Tissue-Type Plasminogen Activator in Healthy Volunteers (1986) (70)
Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1). (1988) (69)
Characterization of the binding of human tissue-type plasminogen activator to platelets. (1989) (69)
Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. (2005) (69)
Low expression VEGF haplotype increases the risk for tetralogy of Fallot: a family based association study (2005) (68)
Nitric oxide inhalation inhibits platelet aggregation and platelet-mediated pulmonary thrombosis in rats. (1997) (68)
Temporal and Topographic Matrix Metalloproteinase Expression after Vascular Injury in Mice (1999) (68)
Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells. (2003) (68)
2 The oxidation hypothesis of atherosclerosis (1997) (68)
Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator. (1988) (68)
On the role of plasminogen activator inhibitor‐1 in adipose tissue development and insulin resistance in mice (2005) (68)
Impaired adipose tissue development in mice with inactivation of placental growth factor function. (2006) (67)
Comparative kinetic analysis of the activation of human plasminogen by natural and recombinant single-chain urokinase-type plasminogen activator. (1986) (67)
Molecular Biology of Human Plasminogen (1975) (67)
Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. (2000) (67)
Gene manipulation and transfer of the plasminogen and coagulation system in mice. (1996) (67)
Gene targeting and gene transfer studies of the plaeminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation, and atherosclerosis (1995) (67)
Increased PA-Inhibitor Levels in the Postoperative Period – No Cause-Effect Relation with Increased Cortisol (1985) (66)
Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction. (1996) (66)
Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis. (2000) (66)
The size of sinusoidal fenestrae is a critical determinant of hepatocyte transduction after adenoviral gene transfer (2004) (65)
Characterization of the interaction between plasminogen and staphylokinase. (1994) (65)
Isolation and characterisation of natural and recombinant staphylokinase (1992) (65)
Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization. (1996) (65)
Inactivation of Plasminogen Activator Inhibitor-1 by Specific Proteolysis with Stromelysin-1 (MMP-3)* (2000) (65)
Correlation between Baseline Plasminogen Activator Inhibitor Levels and Clinical Outcome during Therapy with Tissue Plasminogen Activator for Acute Myocardial Infarction (1991) (65)
Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase (1992) (64)
Deficiency of Urokinase-Type Plasminogen Activator–Mediated Plasmin Generation Impairs Vascular Remodeling During Hypoxia-Induced Pulmonary Hypertension in Mice (2001) (64)
Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activator by the fast-acting inhibitor of plasminogen activator in vitro and in vivo. (1986) (63)
Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin. (1987) (63)
Nonisotopic quantitative analysis of protein-DNA interactions at equilibrium. (1997) (63)
Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease (1995) (62)
Recombinant staphylokinase variants with altered immunoreactivity. IV: Identification of variants with reduced antibody induction but intact potency. (1997) (62)
Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethylketones. (1984) (62)
Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays. (1990) (62)
Comparative Fibrinolytic Properties of Staphylokinase and Streptokinase in Animal Models of Venous Thrombosis (1991) (61)
On the role of the carbohydrate side chains of human plasminogen in its interaction with alpha 2-antiplasmin and fibrin. (1981) (61)
Adeno-associated virus-mediated gene transfer into rat carotid arteries (1997) (61)
Retinoic Acid Induction of Human Tissue-type Plasminogen Activator Gene Expression via a Direct Repeat Element (DR5) Located at −7 Kilobases (*) (1995) (61)
Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus. (1991) (61)
Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation. (1999) (61)
Correlation between Progressive Adsorption of Plasminogen to Blood Clots and Their Sensitivity to Lysis (1990) (61)
Antithrombotic Effects and Bleeding Time Prolongation with Synthetic Platelet GPIIb/llla Inhibitors in Animal Models of Platelet-Mediated Thrombosis (1994) (60)
Fibrinolysis and atherosclerosis. (1988) (60)
Effects of plasminogen activator inhibitor‐1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice (2005) (59)
Molecules in focus Tissue factor (1998) (59)
Immunochemical distinction between antiplasmin and alpha-antitrypsin. (1975) (59)
Antithrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis. (1992) (59)
Stromelysin-1 (MMP-3)-independent gelatinase expression and activation in mice. (1998) (58)
Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop. (1994) (58)
Neuronal Migration Depends on Intact Peroxisomal Function in Brain and in Extraneuronal Tissues (2003) (58)
Absence of Synergism Between Tissue-Type Plasminogen Activator (t-PA), Single-Chain UrokinaseType Plasminogen Activator (scu-PA) and Urokinase on Clot Lysis in a Plasma Milieu In Vitro (1986) (58)
Reactivated Recombinant Plasminogen Activator Inhibitor-1 (rPAI-1) Effectively Prevents Thrombolysis In Vivo (1992) (57)
Fibrinolytic Agents: Mechanisms of Activity and Pharmacology (1995) (57)
Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. (1997) (57)
Targeted deletion of the cytosolic domain of tissue factor in mice does not affect development. (2001) (57)
Adipocyte Hypertrophy in Stromelysin-3 Deficient Mice with Nutritionally Induced Obesity (2002) (57)
Streptokinase‐Induced Platelet Aggregation: Prevalence and Mechanism (1991) (57)
Functional effects of asparagine-linked oligosaccharide on natural and variant human tissue-type plasminogen activator. (1988) (56)
Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit. (1999) (56)
Modulation of Fibrinolytic and Gelatinolytic Activity during Adipose Tissue Development in a Mouse Model of Nutritionally Induced Obesity (2002) (56)
Potentiation by Heparin Fragments of Thrombolysis Induced with Human Tissue-Type Plasminogen Activator or Human Single-Chain Urokinase-Type Plasminogen Activator (1987) (56)
Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. (1990) (56)
Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors (1999) (55)
In vivo studies of a synthetic inhibitor of thrombin. (1982) (55)
Identification of a Multihormone Responsive Enhancer Far Upstream from the Human Tissue-type Plasminogen Activator Gene* (1997) (53)
Characterization of a double homeodomain protein (DUX1) encoded by a cDNA homologous to 3.3 kb dispersed repeated elements. (1998) (53)
Quantitation of the plasma protease inhibitor antiplasmin with the chromogenic substrate S-2251 (1978) (53)
Effect of promoters and enhancers on expression, transgene DNA persistence, and hepatotoxicity after adenoviral gene transfer of human apolipoprotein A-I. (2002) (53)
Soluble Guanylate Cyclase &agr;1 and &bgr;1 Gene Transfer Increases NO Responsiveness and Reduces Neointima Formation After Balloon Injury in Rats via Antiproliferative and Antimigratory Effects (2001) (53)
A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis. (1989) (53)
Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS). (2000) (53)
Characterization of a helicase-like transcription factor involved in the expression of the human plasminogen activator inhibitor-1 gene. (1996) (52)
Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase. (1993) (52)
Oxygen radicals generated during anoxia followed by reoxygenation reduce the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in human endothelial cell culture. (1990) (52)
Characterization of functional domains in human tissue-type plasminogen activator with the use of monoclonal antibodies. (1986) (52)
Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-α, TNF-α converting enzyme and ADAMTS family members in murine fat territories (2003) (51)
Fibrinolytic Response to Venous Occlusion and Fibrin Fragment D-Dimer Levels in Normal and Complicated Pregnancy (1987) (51)
On the Immunogenicity of Recombinant Staphylokinase in Patients and in Animal Models (1994) (50)
Primary structure of human fibrinogen and fibrin. Isolation and partial characterization of chains of fragment D. (1975) (50)
Thrombolytic treatment with recombinant tissue-type plasminogen activator in a patient with massive pulmonary embolism. (1985) (50)
Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase. (1991) (50)
Primary Structure and Gene Structure of Staphylokinase (1992) (50)
Characterization of a recombinant single-chain molecule comprising the variable domains of a monoclonal antibody specific for human fibrin fragment D-dimer. (1991) (50)
Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody (2006) (50)
alpha 2-Antiplasmin consumption and fibrinogen breakdown during thrombolytic therapy. (1979) (50)
Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin. (1989) (50)
Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions. (2010) (49)
A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. (1993) (49)
Polyethylene Glycol–Derivatized Cysteine-Substitution Variants of Recombinant Staphylokinase for Single-Bolus Treatment of Acute Myocardial Infarction (2000) (49)
Thrombolytic and pharmacokinetic properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin (1989) (49)
Histidine-rich glycoprotein in a normal and a clinical population. (1981) (48)
Percutaneous adenoviral gene transfer into porcine coronary arteries: is catheter-based gene delivery adapted to coronary circulation? (1999) (48)
Mechanisms of plasminogen activation (1994) (48)
A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharmacokinetic properties of thrombolytic agents (1990) (47)
Kinetic properties of tripeptide lysyl chloromethyl ketone and lysyl p-nitroanilide derivatives towards trypsin-like serine proteinases. (1980) (47)
Molecular analysis of blood vessel formation and disease. (1997) (47)
The amino terminal lectin-like domain of thrombomodulin is required for constitutive endocytosis. (1997) (47)
HEREDITARY DYSFUNCTIONAL PROTEIN C (PROTEIN C BERGAMO) AND THROMBOSIS (1984) (47)
Role of plasminogen system components in focal cerebral ischemia (1999) (47)
Characterization of recombinant human alpha 2-antiplasmin and of mutants obtained by site-directed mutagenesis of the reactive site. (1987) (46)
Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques (2006) (46)
Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivo. (1990) (46)
On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase-plasminogen complex (BRL 26921). (1981) (46)
Report of the Meeting of the Subcommittee on Fibrinolysis, Jerusalem, Israel, June 2,1986 (1986) (46)
Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer. (2000) (46)
Tissue Plasminogen Activator in Thrombolytic Therapy (1987) (45)
Modulation of the fibrinolytic response of cultured human vascular endothelium by extracellularly generated oxygen radicals. (1992) (45)
Genetic analysis of blood vessel formation role of endothelial versus smooth muscle cells. (1997) (45)
Binding of tissue-type plasminogen activator with human endothelial cell monolayers. Characterization of the high affinity interaction with plasminogen activator inhibitor-1. (1990) (45)
Investigations on the fibrinolytic system in liver cirrhosis. (1968) (45)
Prevalence and Induction of Circulating Antibodies against Recombinant Staphylokinase (1994) (45)
Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction. (2003) (45)
Interaction between staphylokinase, plasmin(ogen), and alpha 2-antiplasmin. Recycling of staphylokinase after neutralization of the plasmin-staphylokinase complex by alpha 2-antiplasmin. (1993) (45)
Biochemical-properties of natural and recombinant staphylokinase (1992) (44)
Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase. (1993) (44)
Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization. (2001) (44)
Lipid emulsions potently increase transgene expression in hepatocytes after adenoviral transfer. (2006) (44)
Characterization Studies on Human Melanoma Cell Tissue Plasminogen Activator (1984) (44)
Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency (1989) (44)
On the molecular interactions between plasminogen-staphylokinase, α2-antiplasmin-formula> and fibrin (1992) (44)
Plasminogen and cell migration in vivo (1999) (44)
Physicochemical, immunochemical and functional comparison of human histidine-rich glycoprotein and autorosette inhibition factor. (1983) (43)
Elimination of a Human T-cell Region in Staphylokinase by T-cell Screening and Computer Modeling (2002) (43)
Structural domains of streptokinase involved in the interaction with plasminogen. (1995) (43)
Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits. (1989) (42)
Impaired fibrinolysis and the risk for coronary heart disease. (1996) (42)
Effect of retinoic acid on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in human endothelial cells. (1991) (42)
α-Thrombin Stimulates Urokinase Production and DNA Synthesis in Cultured Human Cerebral Microvascular Endothelial Cells (1995) (42)
Sustained expression of human apo A-I following adenoviral gene transfer in mice (2001) (42)
Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – IV. Variability in Fibrinolytic Response of Plasma of Several Mammalian Species (1984) (41)
Impaired Adipose Tissue Development in Mice With Inactivation of Placental Growth Factor Function (2006) (41)
Monitoring of Hemostasis Parameters During Coronary Thrombolysis with Recombinant Tissue-Type Plasminogen Activator (1988) (41)
Comparative effects of microplasmin and tissue‐type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice (2004) (41)
Hypercholesterolemia in Minipigs Impairs Left Ventricular Response to Stress: Association With Decreased Coronary Flow Reserve and Reduced Capillary Density (2002) (41)
Both u‐PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis (2002) (41)
Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent. (1989) (41)
Genetic analysis of the plasminogen and coagulation system in mice. (1996) (41)
New approaches to thrombolytic therapy. (1984) (41)
Towards improved thrombolytic therapy (1993) (40)
Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase. (2000) (40)
Single-chain urokinase-type plasminogen activator: mechanism of action and thrombolytic properties. (1987) (40)
Ttrap is an essential modulator of Smad3-dependent Nodal signaling during zebrafish gastrulation and left-right axis determination (2007) (40)
Molecular genetics of the fibrinolytic and coagulation systems in haemostasis, thrombogenesis, restenosis and atherosclerosis. (1997) (40)
Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model. (1990) (39)
Generation of Monoclonal Antibodies against Autologous Proteins in Gene-inactivated Mice (*) (1995) (39)
Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models. (1999) (39)
Active genes in junk DNA? Characterization of DUX genes embedded within 3.3 kb repeated elements. (2001) (39)
Novel Mutation in the Per-Arnt-Sim Domain of KCNH2 Causes a Malignant Form of Long-QT Syndrome (2005) (39)
Influence of fibrin and liver blood flow on the turnover and the systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator in rabbits. (1986) (39)
Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis. (1988) (39)
Structural and Functional Basis of Plasminogen Activation by Staphylokinase (1999) (39)
Thrombolytic agents (2005) (39)
Evaluation of the plasminogen/plasmin system in transgenic mice (1994) (38)
Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis evaluation in transgenic animals. (1995) (38)
Structure-Function Relationships in Staphylokinase as Revealed by "Clustered Charge to Alanine" Mutagenesis (*) (1995) (38)
Reduction in infarct size and enhanced recovery of systolic function after coronary thrombolysis with tissue-type plasminogen activator combined with beta-adrenergic blockade with metoprolol. (1987) (38)
Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator. (1991) (38)
Amino‐acid sequence of human α2‐antiplasmin (1987) (37)
A Role of Plasminogen in Atherosclerosis and Restenosis Models in Mice (1999) (37)
Functional properties of recombinant staphylokinase variants obtained by site-specific mutagenesis of methionine-26. (1994) (37)
Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model. (1992) (37)
PREDICTION OF POSTOPERATIVE LEG-VEIN THROMBOSIS IN GYNÆCOLOGICAL PATIENTS (1978) (37)
Characterization and Targeting of the Murine α2-Antiplasmin Gene (1997) (37)
Targeted gene manipulation and transfer of the plasminogen and coagulation systems in mice (1996) (36)
Comparative fibrinolytic and fibrinogenolytic properties of staphylokinase and streptokinase in plasma of different species in vitro (1992) (36)
Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 2. (2001) (36)
Thrombolytic Profiles of Clot‐Targeted Plasminogen Activators Parameters Determining Potency and Initial and Maximal Rates (1993) (36)
Measurement of free, one-chain tissue-type plasminogen activator in human plasma with an enzyme-linked immunosorbent assay based on an active site-specific murine monoclonal antibody. (1987) (36)
Synergism of thrombolytic agents: investigational procedures and clinical potential. (1988) (36)
Structure-function analyses of thrombomodulin by gene-targeting in mice: the cytoplasmic domain is not required for normal fetal development. (1999) (36)
Notch3 Arg170Cys Knock-In Mice Display Pathologic and Clinical Features of the Neurovascular Disorder Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (2011) (36)
Influence of cyanogen-bromide-digested fibrinogen on the kinetics of plasminogen activation by urokinase. (1984) (36)
Expression of aggrecan(ases) during murine preadipocyte differentiation and adipose tissue development. (2006) (36)
Recombinant staphylokinase variants with altered immunoreactivity. III: Species variability of antibody binding patterns. (1997) (35)
Emerging treatments for thrombocytopenia: increasing platelet production. (2008) (35)
Gene therapy in the cardiovascular system: an update. (1999) (34)
Molecular and cellular basis of fibrinolysis (1995) (34)
Interaction of staphylokinase with different molecular forms of plasminogen. (1993) (34)
Life-Threatening Thrombosis in Mice With Targeted Arg48-to-Cys Mutation of the Heparin-Binding Domain of Antithrombin (2003) (34)
Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo. (1991) (34)
Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis. (1986) (34)
Hypercholesterolemia impairs vascular remodelling after porcine coronary angioplasty. (2002) (34)
Inactivation of the serpin alpha(2)-antiplasmin by stromelysin-1. (2001) (33)
Influence of t-PA and u-PA on Adipose Tissue Development in a Murine Model of Diet-Induced Obesity (2002) (33)
Influence of exogenous and endogenous tissue-type plasminogen activator on the lysability of clots in a plasma milieu in vitro. (1984) (33)
beta-VLDL hypercholesterolemia relative to LDL hypercholesterolemia is associated with higher levels of oxidized lipoproteins and a more rapid progression of coronary atherosclerosis in rabbits. (1997) (33)
In Vitro Fibrinolytic Activity of Recombinant Tissue-Type Plasminogen Activator in the Plasma of Various Primate Species (1984) (33)
Binding Properties of Monoclonal Antibodies against Human Fragment D-Dimer of Cross-Linked Fibrin to Human Plasma Clots in an In Vivo Model in Rabbits (1989) (33)
Histidine-Rich Glycoprotein Modulates the Anticoagulant Activity of Heparin in Human Plasma (1984) (33)
Cardioselective nitric oxide synthase 3 gene transfer protects against myocardial reperfusion injury (2010) (33)
A Pilot Study on Bolus Administration of Recombinant Staphylokinase for Coronary Artery Thrombolysis (1996) (33)
Role of Gas-6 in Adipogenesis and Nutritionally Induced Adipose Tissue Development in Mice (2005) (33)
Characterization of a plasminogen activator secreted by cultured bovine aortic endothelial cells. (1982) (32)
Pharmacology of thrombolytic drugs. (1986) (32)
Molecular Biology of Human Plasminogen (1975) (32)
Pharmacokinetics of single chain forms of urokinase-type plasminogen activator. (1987) (32)
The physiological inhibitors of blood coagulation and fibrinolysis : proceedings of a round-table conference held at the University of Leuven, Belgium, July 22-23, 1978 (1979) (32)
Plasminogen Activator Inhibitor (PA-lnhibitor) Activity in the Blood of Patients with Deep Vein Thrombosis (1985) (32)
Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator with a truncated single chain urokinase-type plasminogen activator. (1987) (32)
Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-alpha, TNF-alpha converting enzyme and ADAMTS family members in murine fat territories. (2003) (32)
Epitope mapping by negative selection of randomized antigen libraries displayed on filamentous phage. (1997) (32)
Quantitation of thrombin‐antithrombin III complexes in human blood (1977) (31)
AN IMMUNOFUNCTIONAL ASSAY FOR ACTIVE PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) (1988) (31)
Characterization of the murine plasminogen/urokinase-type plasminogen-activator system. (1996) (31)
Pharmacokinetics and Coronary Thrombolytic Properties of Two Human Tissue‐Type Plasminogen Activator Variants Lacking the Finger‐Like, Growth Factor‐Like, and First Kringle Domains (Amino Acids 6–173) in a Canine Model (1990) (31)
Purification and Characterization of a Plasminogen Activator Inhibitor 1 Binding Protein from Human Plasma (2001) (31)
Enhancement of the thrombolytic potency of plasminogen activators by conjugation with clot-specific monoclonal antibodies. (1991) (31)
Bleeding time prolongation and bleeding during infusion of recombinant tissue-type plasminogen activator in dogs: potentiation by aspirin and reversal with aprotinin. (1991) (30)
Interaction of Heparin with Histidine-Rich Glycoprotein and with Antithrombin III (1983) (30)
Microplasmin Reduces Ischemic Brain Damage and Improves Neurological Function in a Rat Stroke Model Monitored With MRI (2004) (30)
Adenovirus-Mediated Transfer of Tissue-Type Plasminogen Activator Augments Thrombolysis in Tissue-Type Plasminogen Activator–Deficient and Plasminogen Activator Inhibitor-1–Overexpressing Mice (1997) (30)
Tissue-type plasminogen activator. Mechanisms of action and thrombolytic properties. (1986) (30)
A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma. (1990) (30)
Stimulation by heparin of the plasmin-mediated conversion of single-chain to two-chain urokinase-type plasminogen activator. (1986) (30)
Mechanisms of plasminogen activation by mammalian plasminogen activators. (1988) (30)
Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator. (1988) (30)
Involvement of Sp1 in basal and retinoic acid induced transcription of the human tissue‐type plasminogen activator gene (1999) (29)
Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog. (1992) (29)
Regulation by alpha 2-antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma. (1993) (29)
Synergistic Effect on Thrombolysis of Sequential Infusion of Tissue-Type Plasminogen Activator (t-PA) Single-Chain Urokinase-Type Plasminogen Activator (scu-PA) and Urokinase in the Rabbit Jugular Vein Thrombosis Model (1987) (29)
Synergistic Antithrombotic Properties of G4120, a RGD-Containing Synthetic Peptide, and Argatroban, a Synthetic Thrombin Inhibitor, in a Hamster Femoral Vein Platelet-Rich Thrombosis Model (1992) (29)
Effect of Fibrin-Like Stimulators on the Activation of Plasminogen by Tissue-Type Plasminogen Activator (t-PA) - Studies with Active Site Mutagenized Plasminogen and Plasmin Resistant t-PA (1990) (29)
Generation of Pex5‐loxP mice allowing the conditional elimination of peroxisomes (2002) (29)
Effect of 24 Hours of Normoglycaemia on Tissue-Type Plasminogen Activator Plasma Levels in Insulin Dependent Diabetes (1984) (29)
l-Arginine Administration Reduces Neointima Formation After Stent Injury in Rats by a Nitric Oxide-Mediated Mechanism (2001) (29)
Thrombolytic and Pharmacokinetic Properties of Human Tissue-Type Plasminogen Activator Variants, Obtained by Deletion and/or Duplication of Structural/Functional Domains, in a Hamster Pulmonary Embolism Model (1991) (29)
Mutant and chimeric recombinant plasminogen activators. Production in eukaryotic cells and preliminary characterization. (1987) (29)
On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator. (1991) (28)
NH2-terminal Structural Motifs in Staphylokinase Required for Plasminogen Activation* (1998) (28)
Outcome and One Year Follow-up of Intra-arterial Staphylokinase in 191 Patients with Peripheral Arterial Occlusion (2000) (28)
Preparation, characterization, and turnover properties of heparin-antithrombin III complexes stabilized by covalent bonds. (1982) (28)
Molecular Mechanisms of Fibrinolysis in Man (1978) (27)
Turnover of radiolabelled plasminogen and prothrombin in cirrhosis of the liver (1978) (27)
Stimulation with a monoclonal antibody (mAb4E4) of scavenger receptor-mediated uptake of chemically modified low density lipoproteins by THP-1-derived macrophages enhances foam cell generation. (1994) (27)
Plasminogen Deficiency Differentially Affects Recruitment of Inflammatory Cell Populations in Mice (1998) (27)
Role of the Arg123–Tyr166 Paired Helix of Apolipoprotein A-I in Lecithin:Cholesterol Acyltransferase Activation* (1997) (27)
Fibrinolysis and the control of haemostasis (1987) (27)
Urokinase binds to platelets through a specific saturable, low affinity mechanism (1990) (27)
Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in mice does not affect adipogenesis or adipose tissue development (2006) (27)
Unconventional intronic splice site mutation in SCN5A associates with cardiac sodium channelopathy (2005) (27)
Tiplaxtinin impairs nutritionally induced obesity in mice (2006) (26)
Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor‐1 (PAI‐1) (2004) (26)
Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model. (1992) (26)
Thrombolytic and Pharmacokinetic Properties of a Recombinant Chimeric Plasminogen Activator Consisting of a Fibrin Fragment D-Dimer Specific Humanized Monoclonal Antibody and a Truncated Single-Chain Urokinase (1992) (26)
Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains. (1990) (26)
Neutralization of heparin activity by binding to human histidine-rich glycoprotein. (1983) (26)
Enhanced Fibrinolytic Potential in Mice with Combined Homozygous Deficiency of α2-antiplasmin and PAI-1 (2001) (26)
Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components. (1986) (26)
A monoclonal antibody preventing binding of tissue-type plasminogen activator to fibrin: useful to monitor fibrinogen breakdown during t-PA infusion. (1986) (26)
Fibrin‐specific Fibrinolysis (1992) (26)
Specific proteolysis of human plasminogen by a 24 kDa endopeptidase from a novel Chryseobacterium Sp. (2000) (25)
Urokinase-type plasminogen activator receptor (uPAR) augments brain damage in a murine model of ischemic stroke (2008) (25)
Messenger RNA for human tissue plasminogen activator. (1982) (25)
Turnover of human histidine-rich glycoprotein in healthy subjects and during thrombolytic therapy. (1981) (25)
Purification and Characterization of the Plasminogen Activator Secreted by a Rat Brain Tumor Cell Line in Culture (1981) (25)
An Enzyme-Linked Immunosorbent Assay for Urokinase-Type Plasminogen Activator (u-PA) and Mutants and Chimeras Containing the Serine Protease Domain of u-PA (1992) (25)
Stimulation by Retinoids of Tissue‐Type Plasminogen Activator Secretion in Cultured Human Endothelial Cells: Relations of Structure to Effect (1992) (25)
Percutaneous gene therapy using recombinant adenoviruses encoding human herpes simplex virus thymidine kinase, human PAI-1, and human NOS3 in balloon-injured porcine coronary arteries. (2000) (24)
Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator. (1987) (24)
Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis. (1989) (24)
Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor. (1994) (24)
Coronary thrombolysis with recombinant tissue-type plasminogen activator: patency rate and regional wall motion after 3 months. (1986) (24)
Synthetic Substrates in Clinical Blood Coagulation Assays (1980) (23)
Enhancement of Clot Lysis In Vitro and In Vivo with a Bispecific Monoclonal Antibody Directed against Human Fibrin and against Urokinase-Type Plasminogen Activator (1991) (23)
A latex agglutination test for rapid quantitative estimation of the plasmin–antiplasmin complex in human plasma (1977) (23)
Thrombolysis with Recombinant Human Single-Chain Urokinase-Type Plasminogen Activator (rscu-PA): Dose–Response in Dogs with Coronary Artery Thrombosis (1987) (23)
Characterization of Domain Deletion and/or Duplication Mutants of a Recombinant Chimera of Tissue-Type Plasminogen Activator and Urokinase-Type Plasminogen Activator (rt-PA/u-PAI) (1990) (23)
Mechanisms of Inhibition of Tissue-Type Plasminogen Activator in Blood (1983) (23)
Immunochemical characterization of a low affinity lysine binding site within plasminogen. (1981) (23)
Influence of Hydrostatic Pressure on the Reversible Polymerization of Fibrin Monomers (1970) (23)
Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation. (1993) (23)
Multiple proteases in foot-and-mouth disease virus replication (1984) (23)
Influence of membrane‐bound tumor necrosis factor (TNF)‐α on obesity and glucose metabolism (2004) (23)
Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma. (1991) (22)
Towards better thrombolytic therapy. (1991) (22)
Dynamic structural and functional relationships in recombinant plasminogen activator inhibitor-1 (rPAI-1). (1993) (22)
Modulation of Cell-associated Plasminogen Activation by Stromelysin-1 (MMP-3) (1999) (22)
Restoration of thrombolytic potential in plasminogen-deficient mice by bolus administration of plasminogen (1996) (22)
Adenovirus gene therapy for hypercholesterolemia, thrombosis and restenosis. (1997) (22)
Functional Significance of NH2- and COOH-Terminal Regions of Staphylokinase in Plasminogen Activation (1996) (22)
Guiding a docking mode by phage display: selection of correlated mutations at the staphylokinase-plasmin interface. (1999) (22)
Nucleotide Structure and Characterization of the Murine Blood Coagulation Factor VII Gene (1996) (21)
276 Isolation of a plasminogen activator inhibitor 1 (PAI-1) binding protein from human plasma (1988) (21)
Biological Effects of Combined Inactivation of Plasminogen Activator and Plasminogen Activator Inhibitor-1 Gene Function in Mice (1995) (21)
Effects of Deletion of the Carboxyl-terminal Domain of ApoA-I or of Its Substitution with Helices of ApoA-II on in Vitro and in Vivo Lipoprotein Association* (1996) (21)
The interaction in human plasma of antiplasmin, the fast-reacting plasmin inhibitor, with plasmin, thrombin, trypsin and chymotrypsin. (1977) (21)
Enzymatic properties of single-chain and two-chain forms of a Lys158----Glu158 mutant of urokinase-type plasminogen activator. (1988) (21)
Measurement of different forms of plasminogen activator inhibitor 1(PAI-1) using various monoclonal antibody-based enzyme-linked immunosorbent assays (1990) (21)
New developments in thrombolytic therapy. (1989) (21)
Molecular mechanism of action of newer thrombolytic agents. (1987) (21)
G4120, an Arg-Gly-Asp Containing Pentapeptide, Enhances Arterial Eversion Graft Recanalization with Recombinant Tissue-Type Plasminogen Activator in Dogs (1992) (21)
Inhibition of factor VIII with a partially inhibitory human recombinant monoclonal antibody prevents thrombotic events in a transgenic model of type II HBS antithrombin deficiency in mice (2004) (20)
α2-Antiplasmin Gene Deficiency in Mice Does Not Affect Neointima Formation After Vascular Injury (2000) (20)
213 Thrombus imaging with 123I-labeled Fab fragments of two fibrin fragment D-dimer specific antibodies in a rabbit model of venous thrombosis (1988) (20)
Small Animal Thrombosis Models for the Evaluation of Thrombolytic Agents (1991) (20)
The relevance of clinical and hemostasis parameters for the prediction of postoperative thrombosis of the deep veins of the lower extremity in gynecologic patients. (1980) (20)
Role of α2-Antiplasmin in Fibrin-Specific Clot Lysis with Single-Chain Urokinase-Type Plasminogen Activator in Human Plasma (1991) (20)
Restoration of thrombolytic potential in plasminogen-deficient mice by bolus administration of plasminogen. (1996) (20)
Thrombolysis: Biological and Therapeutic Properties of New Thrombolytic Agents (1986) (20)
Plasminogen-dependent and -independent Proteolytic Activity of Murine Endothelioma Cells with Targeted Inactivation of Fibrinolytic Genes (1997) (19)
Effects of DDAVP and venous occlusion on the release of tissue-type plasminogen activator and von Willebrand factor in patients with panhypopituitarism. (1984) (19)
Aspirin, indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusion. (1985) (19)
Immunochemical characterization of the plasmin-antiplasmin system. Basis for the specific detection of the plasmin-antiplasmin complex by latex agglutination assays. (1979) (19)
Emergence in plasma during activation of the coagulation or fibrinolytic systems of neoantigens, associated with the complexes of thrombin or plasmin with their inhibitors. (1974) (19)
Contribution of platelets and the vessel wall to the antithrombotic effects of a single bolus injection of Fab fragments of the antiplatelet GPIIb/IIIa antibody 7E3 in a canine arterial eversion graft preparation. (1994) (19)
Matrix metalloproteinase deficiencies do not impair cell-associated fibrinolytic activity. (2001) (19)
Thrombus imaging with an I-123-labeled F(ab')2 fragment of an anti-human fibrin monoclonal antibody in a rabbit model. (1989) (19)
Designing thrombolytic agents: focus on safety and efficacy. (1992) (19)
Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons (1992) (19)
Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1. (1992) (19)
Relationship between inflammation and venous thromboembolism as studied by microparticle assessment in plasma. (2005) (19)
Laboratory monitoring of hemostasis during thrombolytic therapy with recombinant human tissue-type plasminogen activator. (1988) (19)
Questions unresolved by the Third International Study of Infarct Survival. (1992) (19)
Staphylokinase, a fibrin-specific bacterial plasminogen activator (1996) (19)
Differential reactivity of Glu-Gly-Arg-CH2Cl, a synthetic urokinase inhibitor, with single-chain and two-chain forms of urokinase-type plasminogen activator. (1987) (19)
Bone marrow transplantation rescues infarct healing, whereas vascular endothelial growth factor fails to increase angiogenesis in urokinase deficient mice after acute myocardial infarction (2000) (18)
Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits (1989) (18)
Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains. (1990) (18)
New developments in thrombolytic therapy. (1990) (18)
Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential. (1995) (18)
Immunochemical distinction between the inhibitors of plasminogen activation and antiplasmin in human plasma. (1976) (18)
Construction and characterization of a functional chimeric murine-human antibody directed against human fibrin fragment-D dimer. (1991) (18)
Procoagulant Properties of Intravenous Staphylokinase Versus Tissue-Type Plasminogen Activator (1996) (17)
Natural inhibitors of fibrinolysis (1980) (17)
Molecular mechanisms of thrombolytic therapy. (1986) (17)
Generation of monoclonal antibodies against autologous proteins in gene-inactivated mice. (1995) (17)
Intravenous thrombolysis with recombinant staphylokinase versus tissue-type plasminogen activator in a rabbit embolic stroke model. (1997) (17)
On the future of thrombolytic therapy for acute myocardial infarction. (1993) (17)
Accelerated thrombin generation during conjunctive treatment of myocardial-infarction with t-pa and r-hirudin (cgp-39-393) (1995) (16)
Synthesis and secretion of plasminogen activator inhibitor 1 by human endothelial cells in vitro. Effect of active site mutagenized tissue-type plasminogen activator. (1991) (16)
Partial Primary Structure of Human α2-Antiplasmin – Homology with Other Plasma Protease Inhibitors (1982) (16)
Staphylokinase-Specific Cell-Mediated Immunity in Humans1 (2002) (16)
Human plasminogen: in vitro and in vivo evidence for the biological integrity of NH2-terminal glutamic acid plasminogen. (1975) (16)
Treatment of prosthetic tricuspid valve thrombosis with recombinant tissue-type plasminogen activator. (1987) (16)
Tissue-Type Plasminogen Activator (1989) (16)
Arginine 719 in human plasminogen mediates formation of the staphylokinase:plasmin activator complex. (1998) (16)
Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice. (1998) (16)
Protease inhibitors of human plasma. Alpha-2-antiplasmin. (1985) (16)
Comparison of the reactions of neutral granulocyte proteases with the major plasma protease inhibitors and with antiplasmin. (1977) (16)
Metabolism of fibrinogen in cirrhosis of the liver. (1971) (16)
Molecular interactions between tissue-type plasminogen activator and plasminogen. (1993) (16)
Revival of Plasmin as a Therapeutic Agent? (2001) (15)
Recent developments in thrombolytic therapy (2000) (15)
387. The Size of Sinusoidal Fenestrae Is a Critical Determinant of Hepatocyte Transduction after Adenoviral Gene Transfer (2004) (15)
Metabolism of iodine-labeled plasminogen during streptokinase and reptilase therapy in man☆☆☆ (1973) (15)
Isolation and conditioning of recombinant staphylokinase for use in man (1993) (15)
Proteolytic enzymes in coagulation, fibrinolysis, and complement activation. Introduction. (1993) (15)
Identification of plasminogen activator releasing activity in the neurohypophysis (1984) (14)
Covalent Complexes Between Low Molecular Weight Heparin Fragments and Antithrombin III – Inhibition Kinetics and Turnover Parameters (1983) (14)
Time course of the effects of a single bolus injection of F(ab')2 fragments of the antiplatelet GPIIb/IIIa antibody 7E3 on arterial eversion graft occlusion, platelet aggregation, and bleeding time in dogs. (1994) (14)
Identification of the human plasma protein which inhibits fibrinolysis associated with malignant cells. (1977) (14)
Fibrinolysis and thrombolysis (1986) (14)
Lack of tPA Significantly Affects Antithrombotic Therapy by a GPIIb/IIIa Antagonist, but not by a Thrombin Inhibitor in Mice (2000) (14)
Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model. (1991) (14)
Quantitative Estimation of Thrombin-Antithrombin III and Plasmin-Alpha1-Antiplasmin Complexes in Human Plasma (1975) (14)
Absence of Potentiation with Murine Antiplatelet GPIIb/IIIa Antibody of Thrombolysis with Recombinant Tissue-Type Plasminogen Activator (rt-PA) in a Canine Venous Thrombosis Model (1989) (14)
Purification and characterization of bovine coagulation factor XII (Hageman factor). (1978) (14)
Feasibility Study of Catheter-directed Thrombolysis with Recombinant Staphylokinase in Deep Venous Thrombosis (1998) (14)
On the molecular interactions between plasminogen-staphylokinase, alpha 2-antiplasmin and fibrin. (1992) (14)
Strokes, statistics and sophistry in trials of thrombolysis for acute myocardial infarction. (1993) (14)
Sensitivity and precision of activated partial thromboplastin time (APTT) methods. A multicenter study. (2009) (14)
Effects of Heparin and Hirudin (CGP 39393) on Thrombin Generation During Thrombolysis for Acute Myocardial Infarction (1995) (14)
Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice. (1997) (14)
Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy. (1986) (14)
Characterization of the high-affinity interaction between human plasminogen and pro-urokinase. (1985) (14)
Arterial neointima formation after trauma in mice with inactivation of the t-PA, u-PA or PAI-1 genes (1994) (13)
Effects of G4120, a Arg-Gly-Asp containing synthetic platelet glycoprotein IIB/IIIA receptor antagonist, on arterial and venous thrombolysis with recombinant tissue-type plasminogen activator in dogs (1993) (13)
Effects of G4120, a Arg-Gly-Asp containing synthetic platelet glycoprotein IIB/IIIA receptor antagonist, on arterial and venous thrombolysis with recombinant tissue-type plasminogen activator in dogs (1993) (13)
Effects of G4120, a Arg-Gly-Asp containing synthetic platelet glycoprotein IIB/IIIA receptor antagonist, on arterial and venous thrombolysis with recombinant tissue-type plasminogen activator in dogs (1993) (13)
New developments in thrombolytic therapy. (1990) (13)
High resolution mapping of the B cell epitopes of staphylokinase in humans using negative selection of a phage-displayed antigen library. (1998) (13)
COMPARATIVE THROMBOLYTIC PROPERTIES OF RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR (RT-PA) AND OF 2 PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) RESISTANT GLYCOSYLATION VARIANTS IN A COMBINED ARTERIAL AND VENOUS THROMBOSIS MODEL IN THE DOG (1993) (13)
Thrombolytic Therapy (1991) (13)
Prostromelysin-1 (proMMP-3) stimulates plasminogen activation by tissue-type plasminogen activator. (2000) (13)
Thrombolytic therapy. (1997) (13)
Inhibition of vascular endothelial growth factor receptor tyrosine kinases impairs adipose tissue development in mouse models of obesity. (2007) (13)
Recombinant tissue-type plasminogen activator. (1991) (13)
PLASMA LEVELS OF FRAGMENT D-DIMER OF CROSSLINKED FIBRIN DURING THROMBOLYTIC THERAPY WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR (1987) (13)
Fibrin-selective thrombolytic therapy with recombinant staphylokinase. (1996) (13)
CORONARY THROMBOLYSIS WITH INTRAVENOUSLY ADMINISTERED HUMAN PRO-UROKINASE IN DOGS (1985) (13)
A dose-finding clinical trial of staphylokinase SY162 in patients with long-term venous access catheter thrombotic occlusion (2007) (13)
Adenovirus-mediated transfer of soluble guanylayte cyclase alpha 1 and beta 1 subunits increases nitric oxide responsiveness and reduces neointima formation in balloon-injured rat carotid arteries (1998) (13)
Role of the carboxy-terminal domain of human apolipoprotein AI in high-density-lipoprotein metabolism--a study based on deletion and substitution variants in transgenic mice. (1997) (13)
Comparison of a low‐molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs (1995) (13)
Critical role of glutamic acid 202 in the enzymatic activity of stromelysin-1 (MMP-3). (2001) (12)
Alpha-thrombin stimulates urokinase production and DNA synthesis in cultured human cerebral microvascular endothelial cells. (1995) (12)
A new approach to thrombolytic therapy (1981) (12)
Adenovirus-mediated gene transfer of rt-PA restores thrombolysis in t-PA deficient mice (1994) (12)
Regulation of Fibrinolysis: Plasminogen Activator as a Thrombolytic Agent (1982) (12)
The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin (2001) (12)
Molecular mechanisms of thrombolysis: implications for therapy. (1990) (12)
Properties of staphylokinase and its potential as a thrombolytic agent (1995) (12)
Comparative Effects of Enoxaparin and Heparin on Arterial and Venous Clot Lysis with Alteplase in Dogs (1993) (12)
Fibrin-specific thrombolytic agents. (1987) (12)
Reperfusion in acute myocardial infarction (2005) (12)
Transgenic animals as tools for the study of fibrinolysis in vivo (1994) (12)
1,25‐Dihydroxyvitamin D3 induction of the tissue‐type plasminogen activator gene is mediated through its multihormone‐responsive enhancer (1999) (12)
Biochemical and Biological Properties of a Recombinant Tissue-Type Plasminogen Activator Derived from the Rat JMI-229 Cell Line (1992) (12)
Characterisation of a chemical conjugate between a low molecular weight form of recombinant single chain urokinase-type plasminogen activator (comprising Leu144 through Leu411) and F(ab′)2-fragments of a fibrin D-dimer-specific monoclonal antibody (1990) (12)
A case of IgM antibodies which inhibit the contact activation of blood coagulation. (1978) (12)
Letter: The fibrinogenolytic pathway of fibrinogen catabolism: a reply. (1974) (11)
COMPETITIVE-INHIBITION BY HUMAN-PLASMA OF THE ACTIVATION OF PLASMINOGEN BY PRO-UROKINASE (1985) (11)
Reperfusion in acute myocardial infarction. International Society and Federation of Cardiology and World Health Organization Task Force on Myocardial Reperfusion. (1994) (11)
Activation of the fibrinolytic system. (1987) (11)
Alpha(2)-antiplasmin gene deficiency in mice does not affect neointima formation after vascular injury. (2000) (11)
Characterisation of a mutant of recombinant human single chain urokinase-type plasminogen activator (scu-PA), obtained by substitution of arginine 156 and lysine 158 with threonine (1988) (11)
New strategies in the development of thrombolytic agents. (1988) (11)
Cloning and Characterization of a cDNA Encoding Murine Coagulation Factor X (1998) (11)
Thrombolytic therapy for unstable angina pectoris: rationale and results. (1987) (11)
Degradation of the apoprotein A-I polypeptide chain of human high density lipoprotein by human plasmin. (1981) (11)
Plasminogen/plasmin system function in mice deficient in stromelysin-1 (MMP-3) or in tissue inhibitor of metalloproteinases type-1 (TIMP-1) (1998) (11)
Nucleotide Structure and Characterization of the Murine Gene Encoding Anticoagulant Protein C (1998) (11)
Coronary thrombolysis with K1K2PU, a chimeric tissue‐type and urokinase‐type plasminogen activator: A feasibility study in six patients with acute myocardial infarction (1993) (11)
Engineered staphylokinase variants with reduced immunogenicity (1998) (11)
Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase. (1992) (11)
Changes in antigenic structure and conformation of alpha 2-antiplasmin induced by interaction with plasmin. (1980) (11)
α2-ANTIPLASMIN INHIBITOR DEFICIENCY (1979) (11)
Relevance of Free tPA Assay Following Venous Occlusion in Patients with Venous Thromboembolic Disease (1988) (11)
Affinity chromatography of soluble fibrin in human plasma on insolubilized fibrinogen and fragment D. (1978) (11)
Persistent inhibition of arterial thrombosis by a 1‐hour intravenous infusion of argatroban, a selective thrombin inhibitor (1992) (11)
Fibrin-specific thrombolytic therapy. (1988) (10)
Plasminogen/plasmin and matrix metalloproteinase system function in mice with targeted inactivation of stromelysin-3 (MMP-11) (1998) (10)
Tissue-Type Plasminogen Activator (2012) (10)
Coronary thrombolysis and infarct sizes reduction following intravenous infusion of recombinant tissue-type plasminogen activator in non-human primates (1984) (10)
PRO-UROKINASE - KINETICS AND MECHANISM OF ACTION (1985) (10)
Prothrombin metabolism in healthy subjects and in two patients with congenital hypoprothrombinemia (1975) (10)
Neoantigenic expression in enzyme-inhibitor complexes. A means to demonstrate activation of enzyme systems. (1978) (10)
Molecular Conversions of Recombinant Staphylokinase During Plasminogen Activation in Purified Systems and in Human Plasma (1993) (10)
Intracranial haemorrhage with bolus thrombolytic agents (2000) (10)
Enzymatic properties of phage-displayed fragments of human plasminogen. (1997) (10)
Interaction of Heparin with Histidine‐rich Glycoprotein (1989) (10)
Antithrombotic properties in rabbits of heparin and heparin fragments covalently coupled to human antithrombin III. (1985) (10)
Direct quantitation of oxidized low-density-lipoprotein (oxldl) and assessment of its pole in atherothrombosis in end-stage renal-disease (esrd) patients (1995) (9)
Molecular mechanism of fibrinolysis. (1984) (9)
Tissue-type plasminogen activator. Therapeutic potential in thrombotic disease states. (1986) (9)
Plasmin-antiplasmin complex formation during defibrase infusion in man. (1977) (9)
Coronary thrombolysis with tissue-type plasminogen activator: an overview. (1985) (9)
Comparative antigenicity of recombinant wild-type staphylokinase (SakSTAR) and a selected mutant (SakSTAR.M38) in a baboon thrombolysis model. (1996) (9)
tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor. (2000) (9)
Tissue-type plasminogen activator: mutants, variants, and adjunctive treatment. (1989) (9)
Intracranial hemorrhage after rt-pa and heparin for acute myocardial infarction — The TIMI II pilot and randomized trial combined experience (1990) (9)
EXPERIMENTAL STUDIES IN THROMBOLYSIS AND FIBRINOLYSIS (1993) (9)
Thrombin-Antithrombin III and Plasm in-Antiplasmin Complexes as Indicators of in Vivo Activation of the Coagulation and/or Fibrinolytic Systems (1977) (9)
Characterisation of conjugates of thrombin-treated single chain urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin (1990) (9)
Regulation of the fibrinolytic system (1993) (9)
Fibrinolytic system and its disorders (1995) (9)
New developments in the molecular biology of coagulation and fibrinolysis (1999) (9)
Antibodies against oxidized LDL for non-invasive diagnosis of atherosclerotic vascular disease. (2001) (9)
Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase. (1992) (9)
The Arg123-Tyr166 central domain of human ApoAI is critical for lecithin:cholesterol acyltransferase-induced hyperalphalipoproteinemia and HDL remodeling in transgenic mice. (2000) (9)
Effects of the synthetic fibrinolytic agents ortho-thymotic acid and S-1623 on the reaction between human plasmin and antiplasmin. (1978) (9)
On the molecular interactions between fibrin, tissue-type plasminogen activator and plasminogen. (1990) (9)
1. Generation by Homologous Recombination and Characterization (1993) (9)
Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis. (1990) (8)
Prevalence and Mechanism (2005) (8)
NEUTRALIZATION OF HEPARIN ACTIVITY BY BINDING TO HISTIDINE-RICH GLYCOPROTEIN IN PURIFIED SYSTEMS AND IN HUMAN-PLASMA (1983) (8)
Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator. (1992) (8)
Affinity chromatography of soluble fibrin in human plasma on insolubilized fibrinogen and on fragment D from fibrinogen, non cross-linked or cross-linked fibrin. (1978) (8)
Induction of t-PA Synthesis with intravenous bolus injection of vitamin A palmitate in vitamin a deficient rats (1992) (8)
Differential Inhibition with Antifibrinolytic Agents of Staphylokinase and Streptokinase Induced Clot Lysis (1995) (8)
Coronary thrombolysis in perspective : principles underlying conjunctive and adjunctive therapy (1993) (8)
Role of the Plasminogen and MMP Systems in Wound Healing (2003) (8)
Development of novel thrombolytic agents (1994) (8)
The plasminogen system and cell migration during an inflammatory response (1996) (8)
Receptor-independent plasminogen activation by urokinase-type plasminogen activator promotes, and adenoviral pai-1 gene transfer inhibits arterial neointima formation in mice (1996) (8)
Kinetics Of Plasminogen Activation By Tissue Plasminogen Activator. Role Of Fibrin (1981) (8)
Thrombolytic Agents in Development (1995) (8)
Interactions of Staphylokinase with Human Platelets (1995) (8)
Influence of oral intake of retinoids on the human plasma fibrinolytic system (1993) (8)
Metabolism of iodine labeled plasminogen and prothrombin in cirrhosis of the liver (1972) (8)
CD9 Gene Deficiency Does not Affect Smooth Muscle Cell Migration and Neointima Formation after Vascular Injury in Mice (2000) (8)
Turnover of histidine-rich glycoprotein during heparin administration in man. (1983) (8)
Screening panels of monoclonal antibodies using phage-displayed antigen. (1997) (8)
A monoclonal antibody directed against the high-affinity lysine-binding site (LBS) of human plasminogen. Role of LBS in the regulation of fibrinolysis. (1986) (8)
Semi-automatic method for routine evaluation of fibrinolytic components (1968) (8)
Construction and characterization of a recombinant murine monoclonal antibody directed against human fibrin fragment-D dimer. (1990) (8)
Comparative Effects of Staphylokinase and Alteplase in Rabbit Bleeding Time Models (1996) (8)
Binding of streptokinase and staphylokinase to plasminogen (1995) (8)
MEASUREMENT OF PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) IN PLASMA WITH AN ELISA BASED ON TWO MURINE MONOCLONAL ANTIBODIES (1987) (8)
Adenovirus-mediated gene transfer of human PAF-AH prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apoE(-/-) mice (2001) (7)
Molecular basis of thrombolytic therapy (2000) (7)
Development of thrombolytic agents. (1993) (7)
Fibrin-specific thrombolytic agents. (1988) (7)
The fibrinolytic system in man: an overview (1985) (7)
Plasminogen deficiency leads to stagnant wound healing following myocardial infarction in mice (1998) (7)
Expression and Characterization of Clustered Charge-to-Alanine Mutants of Low Mr Single-Chain Urokinase-Type Plasminogen Activator (1994) (7)
Pilot-study of combined administration of ridogrel and alteplase in patients with acute myocardial-infarction (1991) (7)
Toxicology Studies with Recombinant Staphylokinase and with SY 161-P5, a Polyethylene Glycol-Derivatized Cysteine-Substitution Mutant (2001) (7)
Antithrombotic effects of thrombolytic agents in a platelet-rich femoral vein thrombosis model in the hamster. (1995) (7)
TOWARDS THE DEVELOPMENT OF IMPKOVED THROMBOLYTIC AGENTS (1991) (7)
Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator. (1990) (7)
Inactivation of the mouse urokinase-receptor gene (1994) (7)
Gene inactivation of U-PA or adenoviral gene transfer of tissue inhibitor of metalloproteinases-1 impedes cardiac hypertrophy and fibrosis, but improves cardiac function during hypertension in mice (2000) (7)
Cardiovascular system disorders (1991) (6)
Amino-acid sequence of human alpha 2-antiplasmin. (1987) (6)
Cardiomyocyte-specific NOS3 Overexpression Protects Against Chronic Pressure Overload-induced LV Hypertrophy and Dysfunction (2004) (6)
Kinetics of the Inhibition of Plasmin in Acidified Human Plasma (1982) (6)
Plasminogen Binding Properties of Macrophage Inflammatory Protein (MIP)-2α (2000) (6)
Effect of Ridogrel, a Combined Thromboxane A2 Synthase Inhibitor/ Prostaglandin Endoperoxide Receptor Antagonist, on the Lysis of Platelet- rich Coronary Arterial Thrombi with Recombinant Tissue-type Plasminogen Activator in a Canine Model (1992) (6)
Thrombolysis with human tissue-type plasminogen activator (1985) (6)
Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits. (1989) (6)
Thrombolysis with Bolus Injections and Infusions of Tissue-type Plasminogen Activator in Rabbits with Experimental Jugular Vein Thrombosis (1991) (6)
The interaction between components of the fibrinolytic system and GPIb/V/IX of platelets thrombus formation in mice (2000) (6)
Enzyme-linked immunosorbent assay for the specific detection of angiostatin-like plasminogen moieties in biological samples. (2001) (5)
Thrombolytic properties of t-PA in experimental venous occlusion and in patients with venous thrombosis (1985) (5)
Accelerated thrombin generation during anticoagulation in patients with unstable angina pectoris. (1994) (5)
Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala. (1992) (5)
Pharmacokinetic properties of mutants of recombinant single chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160 (1990) (5)
Conjunctive antithrombotic and thrombolytic therapy for acute myocardial infarction (1992) (5)
, John and Pulmonary Vascular Remodeling Cytochrome P 450 Epoxygenase Gene Function in Hypoxic Pulmonary Vasoconstriction (2006) (5)
The effects of disruption of plasminogen gene on vascular neointima formation: Analysis by the external vascular cuff-induced neointima formation mouse model (2000) (5)
Is there an optimal thrombolytic regimen? (1994) (5)
Coronary thrombolysis with clot-selective plasminogen activators. (1986) (5)
Regulation and Control of the Fibrinolytic System (1990) (5)
Potential approaches for therapeutic intervention of thrombosis by fibrinolytic agents. (1988) (5)
Reduction of in-stent restenosis in porcine coronary arteries after local delivery of adenovirus encoding NOS3 (1999) (5)
10 New thrombolytic agents and strategies (1995) (5)
Single-chain urokinase-type plasminogen activator (prourokinase) (1996) (5)
Regional wall motion and coronary patency rate after intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA): long-term results (1986) (4)
Effects of fibrin-targeting and clearance rate on the thrombolytic potency of chimeric plasminogen activators consisting of a single-chain Fv fragment derived from a fibrin-specific antibody and single-chain u-PA (scu-PA) (1992) (4)
MUTANT AND CHIMAERIC RECOMBINANT PLASMINOGEN ACTIVATORS (1987) (4)
A randomized placebo controlled trial on the effects of simvastatin, a HMG-CoA reductase inhibitor, on blood lipids and fibrinolytic parameters. (1992) (4)
The role of the active center and lysine binding sites in plasmin-induced platelet activation (1990) (4)
Prominin–1 Deficiency Leads to Progressive Retinal Degeneration (2005) (4)
Increased levels of oxidized LDL in obese patients are normalised by treatment with atorvastatin (2000) (4)
Rebuttal: Synergism of Tissue-Type Plasminogen Activator (t-PA) and Single-Chain Urokinase-Type Plasminogen Activator (scu-PA) on Clot Lysis In Vitro and a Mechanism for this Effect (1987) (4)
A FUSION PROTEIN OF THE A-CHAIN OF t-PA WITH LOW Mr scu-PA COMBINES THE FIBRIN-SPECIFICITY OF BOTH MOLECULES (1987) (4)
CHARACTERIZATION OF SINGLE CHAIN UROKINASE-TYPE PLASMINOGEN ACTIVATOR MUTANTS PRODUCED BY SITE-SPECIFIC MUTAGENESIS OF LYS (1987) (4)
Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA. (1989) (4)
Thrombophilia in mice expressing a tissue factor variant lacking its transmembrane and cytosolic domain. (2005) (4)
The fibrinolytic enzyme system (1990) (4)
Tissue factor. (1998) (4)
MOLECULAR-BASIS OF THE DIFFERENTIAL RESPONSE OF THE HUMAN AND CANINE PLASMA FIBRINOLYTIC SYSTEMS TO ACTIVATION WITH STREPTOKINASE AND WITH RECOMBINANT STAPHYLOKINASE (1993) (4)
Impairment of adipose tissue development by hypoxia is not mediated by plasminogen activator inhibitor-1 (2005) (4)
MONOCLONAL-ANTIBODIES DIRECTED AGAINST THE FIBRIN-BINDING SITE OR THE ACTIVE-SITE OF HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR (T-PA) (1985) (4)
Regulation of the fibrinolytic system during gonadotropin-induced ovulation in mice with inactivation of the genes encoding tPA, uPA or PAI-i (1994) (4)
Prevalence and mechanism of streptokinase induced platelet aggregation (1989) (4)
Comparative copper coil-induced thrombogenicity of the internal mammary, left anterior descending coronary, and popliteal arteries in dogs. (1992) (4)
Lipid lowering and enhancement of fibrinolysis with niacin. (1995) (4)
ANTITHROMBOTIC PROPERTY OF G4120, A CYCLIC ARG-GLY-ASP CONTAINING PEPTIDE, IN A HAMSTER PLATELET-RICH FEMORAL VEIN-THROMBOSIS MODEL (1991) (4)
Coronary Reperfusion in Patients with an Acute Myocardial Infarction following Intravenous Administration of Recombinant Staphylokinase (1994) (4)
Remaining Perspectives of Mutant and Chimeric Plasminogen Activators (1992) (4)
IMMUNOLOGICAL SIMILARITIES BETWEEN PLASMA AND URINARY PROTEIN C INHIBITORS (PCIs) AND URINARY UROKINASE INHIBITOR (UKI) (1987) (4)
Pharmacology of thrombolytic agents (2003) (4)
Thrombolytic therapy. (1991) (4)
Thrombolysis: is there a future for thrombolytic therapy in acute myocardial infarction? (1991) (4)
Biochemical and biological properties of single-chain urokinase-type plasminogen activator. (1986) (4)
Nigral degeneration following striato-pallidal lesion in tissue type plasminogen activator deficient mice (1999) (4)
Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis. (1995) (4)
Glomerulonephritis in mice with genetic deficiencies of the plasminogen system (1996) (4)
Purification and partial primary structure of cyanogen bromide fragments from human α2-antiplasmin (1982) (4)
Preexisting antiadenoviral immunity and regional myocardial gene transfer: modulation by nitric oxide. (2002) (4)
The fibrinolytic system: implications for thrombolytic therapy (1995) (4)
SYNERGISM, MUTANTS AND HYBRIDS OF TISSUE-TYPE PLASMINOGEN ACTIVATO(t-PA) AND SINGLE CHAIN UROKINASE-TYPE PLASMINOGEN ACTIVATOR(scu-PA):POTENTIAL FORTHROMBOLYTIC THERAPY (1987) (3)
Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. (1992) (3)
[Randomized double-blind study comparing tissue-type plasminogen activator with placebo in acute myocardial infarct]. (1988) (3)
CHARACTERIZATION OF A SINGLE-CHAIN RECOMBINANT PLASMINOGEN-ACTIVATOR CONSISTING OF A FV FRAGMENT DERIVED FROM A D-DIMER SPECIFIC ANTIBODY AND LOW-MOLECULAR-WEIGHT SINGLE-CHAIN UROKINASE (RSCU-PA-32K) (1991) (3)
THROMBUS IMAGING WITH MURINE MONOCLONAL ANTIBODIES AGAINST FIBRIN FRAGMENT D-DIMER IN A RABBIT JUGULAR VEIN THROMBOSIS MODEL (1987) (3)
Interface scanning and 3D model of the staphylokinase: plasmin activator complex (1998) (3)
[Tissue plasminogen activator: mechanism of action and thrombolytic properties]. (1986) (3)
On The Fibrinolytic Properties Of Single-Chain And Two- Chain Human Tissue Plasminogen Activator (1981) (3)
Human-like HDL -in vivo- reduces oxidative stress, Ca2+ transients, adhesion molecule expression and macrophage homing in apoE deficient mice (1999) (3)
Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160. (1988) (3)
Dissecting aneurysm of the descending aorta: a frequently unrecognized condition with overrated fatality. (1970) (3)
Thrombolytic Properties Of Purified Human Tissue Plasminogen Activator In A Dog Femoral Vein Thrombosis Model (1981) (3)
PURIFICATION AND CHARACTERIZATION OF PRO-UROKINASE FROM HUMAN-URINE AND CONDITIONED CELL-CULTURE MEDIA (1985) (3)
[Thrombolysis with tissue-type plasminogen activator in acute myocardial infarct]. (1984) (3)
New thrombolytic agents and strategies. (1995) (3)
Expression and characterization of clustered charge-to-alanine mutants of low M(r) single-chain urokinase-type plasminogen activator. (1994) (3)
Coronary thrombolysis in baboons after intravenous administration of recombinant tissue-type plasminogen-activator (rt-pa) (1984) (3)
Comparison of the partial primary structure of human alpha2-antiplasmin with other plasma protease inhibitors (1983) (3)
Anticoagulants, platelet controlling drug and thrombolytic agents (1990) (3)
Transfection of human endothelial cells with plasminogen activator inhibitor type-1 promoter/reporter gene fragments reveals phorbol ester induction of gene expression (1992) (3)
Coronary thrombolysis indogswithintravenously administered humanpro-urokinase (1985) (3)
Activation of plasminogen by natural single-chain urokinase-type plasminogen activator (1986) (3)
Optimising Thrombolytic Therapy in Elderly Patients with Acute Myocardial Infarction (1996) (3)
Single bolus administration of polyethylene glycol-derivated cysteine-substitution variants of recombinant staphylokinase in acute myocardial infarction (1999) (3)
Phase I Clinical Trial of a Novel, Long-Acting Antithrombotic Drug: A Human Monoclonal Antibody Partially Inhibiting FVIII Activity. (2007) (3)
Bio-Immunoassay for Staphylokinase in Blood (1993) (3)
Inhibition Of Human Tissue Plasminogen Activator By Human Plasma : No Evidence For A Specific Antiactivator (1981) (3)
A monoclonal antibody against tissue factor prevents platelet-rich arterial thrombosis in the rabbit (1990) (3)
Letter to the Editor. Intracranial haemorrhage with bolus thrombolytic agents (2000) (3)
Pharmacokinetics of human tissue-type plasminogen activator (t-PA) (1985) (3)
After ISIS-3 (1992) (3)
Modification of a tyrosine residue in the carboxyterminal portion of human alpha2-antiplasmin. (1985) (3)
Recombinant staphylokinase for thrombolytic therapy (1997) (3)
VEGF, a modifier of motor neuron degeneration in SOD1 G93A mice, protects against motor neuron loss after spinal cord ischemia: evidence for a vascular hypothesis (2003) (3)
Inhibition in Purified Systems and in Human Plasma of Chimaeric Plasminogen Activators Consisting of the NH2-Terminal Region of Tissue-Type Plasminogen Activator and the COOH-Terminal Region of UrokinaseType Plasminogen Activator (1988) (3)
Deletion of the hypoxia-response element in the VEGF promoter causes adult onset motor neuron degeneration (2002) (3)
II. Effects on Hemostasis, Thrombosis, and Thrombolysis (1993) (3)
Circulating oxidized LDL is a useful marker for cardiovascular risk assessment (2001) (3)
Hormonal regulation of the expression of fibrinolytic components in HT1080 fibrosarcoma and endothelial cells (1997) (2)
Molecular Analysis of Vascular Development and Disorders (1999) (2)
Combination of animal models and biotechnologies in the development of new thrombolytic agents (1993) (2)
Tissue-type plasminogen activator: helping patients with acute myocardial infarction (2001) (2)
Development of chimeric tissue-type/urokinase-type plasminogen activators for thrombolytic therapy (1993) (2)
Chapter 8 Fibrinolysis and thrombolysis (1986) (2)
Generation and characterization of factor X deficient mice (1998) (2)
Stromelysin-1 (MMP-3)-Independent Gelatinase Expression and Activation in Mice (1998) (2)
Novel thrombolytic agents for treatment of acute myocardial infarction (2003) (2)
A coagulo-radioimmunometric assay for the quantitation of fibrin monomer in human plasma. Principles and development of the method. (1979) (2)
Differential development of hypoxia-induced pulmonary hypertension and right ventricular hypertrophy in transgenic mice with various deficiencies in the plasminogen/plasmin system (1999) (2)
A SENSITIVE BIOINALNOASSAY (BIAS) FOR TISSUE PLASMINOGEN ACTIVATOR IN PLASMA: A REPLACEMENT FOR THE EUGLOBULIN CLOT LYSIS TIME (ECLT) ASSAY (1988) (2)
Placental growth factor 2--A potential therapeutic strategy for chronic myocardial ischemia. (2016) (2)
Adenoviral Gene Transfer of Human Constitutive Endothelial Nitric Oxide Synthase to Injured Coronary Arteries (1997) (2)
HDL-associated PAF-AH reduces endothelial adhesiveness in apoE 2 / 2 mice (2000) (2)
PRIMARY STRUCTURE OF HUMAN ALPHA-2-ANTIPLASMIN (1986) (2)
alpha2-Antiplasmin inhibitor deficiency. (1979) (2)
New thrombolytic agents (1990) (2)
Development of new fibrinolytic agents (1994) (2)
ON THE MECHANISM OF THE IN VIVO SYNERGISM BETWEEN TISSUE-TYPE PLASMINOGEN ACTIVATOR (t-PA) AND SINGLE CHAIN UROKINASE-TYPE PLASMINOGEN ACTIVATOR (scu-PA) (1987) (2)
The Main Components of the Fibrinolytic System: Biochemical and Physiological Properties (1985) (2)
Pilot study of combined administration of ridogrel and rt-PA in patients with acute myocardial infarction (AMI) (1991) (2)
Growth Arrest-Specific Gene 6 (Gas6) Deficiency in Mice Alleviates Graft-versus-Host Disease (GVHD) in the Liver. (2004) (2)
Biological and thrombolytic properties of recombinant urokinase and pro-urokinase (1985) (2)
PROPERTIES OF A HUMAN RECOMBINANT FUSION PROTEIN OF THE ‘FINGER’ DOMAIN OF TISSUE-TYPE PLASMINOGEN ACTIVATOR (t-PA) AND A TRUNCATED SINGLE CHAIN UROKINASE-TYPE PLASMINOGEN ACTIVATOR (scu-PA) (1987) (2)
Interaction of plasminogen activators with fibrinogen and fibrin (1987) (2)
282 Functional properties of chimaeric molecules containing structural domains of tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA) (1988) (2)
Sustained Placental Growth Factor-2 Treatment Does Not Aggravate Advanced Atherosclerosis in Ischemic Cardiomyopathy (2017) (2)
Treatment of disseminated intravascular coagulation. (1983) (2)
Functional Properties of p-Anisoylated Plasmin-Staphylokinase Complex (1993) (2)
Correlation between progressive adsorption of plasminogen to blood clots immersed in a plasma milieu and clot sensitivity to lysis (1990) (2)
Antiplatelet antibody-plasminogen activator conjugates for targeted thrombolysis (1994) (2)
Role of Plasmin and uPAR in Bone Marrow HSC/HPC Retention and Mobilization. (2005) (2)
Biological and Thrombolytic Properties of Natural and Recombinant Human Tissue-Type Plasminogen Activator (t-PA) (1985) (2)
Laboratory Investigation Thrombolytic andPharmacokinetic Properties ofaConjugate ofRecombinant Single-Chain Urokinase-Type Plasminogen Activator WithaMonoclonal Antibody Specific forCross-Linked Fibrin ina BaboonVenousThrombosis Model (1990) (2)
Biological Effects of Inactivation of the Genes for Tissue-type Plasminogen Activator, Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Mice (1993) (2)
Prolonged L-Arginine administration but not inducible nitric oxide synthase gene transfer reduces neointima formation after stent injury in rats (2001) (2)
Coronary thrombolysis with human tissue-type plasminogen activator produced by recombinant DNA technology (1983) (2)
Partial Primary Structure Of Human α2-Antiplasmin (1981) (2)
Potentiation by heparin fragment CY 222 (Choay) of thrombolysis induced by human tissue-type plasminogen activator. (1989) (2)
Promoter dependence of persistence of the effect of the human apo E enhancer on human apolipoprotein A-I expression after adenoviral gene transfer is partially explained by promoter attenuation (1999) (1)
MODULATION OF THE ANTICOAGULANT ACTIVITY OF HEPARIN IN HUMAN-PLASMA BY HISTIDINE-RICH GLYCOPROTEIN (1984) (1)
78 Receptor-independent role of urokinase-type plasminogen activator during vascular wound healing in mice (1997) (1)
Percutaneous adenovirus-mediated gene transfer to reduce restenosis in porcine coronary arteries (1998) (1)
Covalent interaction in the tpa-plasminogen activator inhibitor-1 (pai-1) complex is required for its dissociation from endothelial-cells (1989) (1)
Effects of deletion or substitution of the carboxyterminal domain of human apolipoprotein A-I on high density lipoprotein metabolism in transgenic mice (1996) (1)
Abstract Oral communications III-3: Regulation of gene expression: 2Identification of genomic sequences involved in the induction of human t-PA gene expression by steroid hormones and retinoic acid (1994) (1)
Adenoviral Mediated NOS3 Gene Transfer in Porcine Coronary Arteries Reduces In Stent Restenosis (1999) (1)
Basic Aspects of Fibrinolysis and Thrombolysis (2002) (1)
Activation of the fibrinolytic system during reptilase therapy and following strenuous physical exercise in man (1978) (1)
Interaction between Staphylokinase , Plasmin ( ogen ) , and a 2-Antiplasmin (2001) (1)
4 Interaction of recombinant tissue-type plasminogen activator (rt-PA) and murine anti-platelet GPIIb/IIIa monoclonal antibody in a canine femoral vein thrombosis model (1988) (1)
Immunoscintigraphy of thrombi. (1991) (1)
Intracoronary transplantation of labelled mesenchymal stem cells post myocardial infarction is associated with increased angiogenesis but fails to enhance functional recovery (2005) (1)
A Possible Explanation for Resistance (2005) (1)
Thrombolytic properties of a recombinant humanized antifibrin antibody/urokinase-type plasminogen activator chimera (1992) (1)
77 Urokinase-generated plasmin induces athero-sclerotic aneurysm formation via activation of matrix metalloproteinases (1997) (1)
Role of urokinase-type plasminogen activator in ventricular wall rupture, scar formation, and cardiac function after myocardial infarction (1999) (1)
Impaired wound healing in mice lacking placental growth factor (1997) (1)
Erratum: Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis (Nature (1998) 394 (485-490)) (1998) (1)
Intracoronary gene transfer efficacy: comparison of local delivery catheters in pigs (1998) (1)
Molecular conversions of recombinant staphylokinase in purified systems and in human plasma during plasminogen activation (1993) (1)
Molecular and Cellular Angiogenesis (2002) (1)
Fibrin-specific thrombolysis with tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) (1988) (1)
On the reversible interaction of recombinant plasminogen activator inhibitor-1 (rPAI-1) with different molecular forms of tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA) (1990) (1)
Cardiomyocyte-specific endothelial Nitric Oxide synthase overexpression limits left ventricular remodeling after myocardial infarction in mice (2002) (1)
Persistence of arterial eversion graft patency up to 24 hours following a one hour infusion of argatroban: A selective thrombin inhibitor (1991) (1)
Overexpression of a mutant, cGMP-independent protein kinase reduces restenosis in stented porcine coronary arteries (2001) (1)
ISIS-3 : implications for american practice. Medical panel discussion (1991) (1)
Characterization of a human plasma protein with affinity for the lysine-binding sites in plasminogen and antifibrinolytic properties (1981) (1)
Fibrin-specific thrombolytic agents. (1987) (1)
Thrombolytic therapy of acute myocardial infarction. (1991) (1)
76 Reduced transplant arteriosclerosis in plasminogen deficient mice (1997) (1)
Alpha2-antiplasmin gene deficiency in mice does not affect neointima formation after vascular injury (2000) (1)
EFFECT OF DIFFERENT HEPARINS ON THROMBOLYSIS WITH t-PA AND scu-PA IN RABBITS WITH EXPERIMENTAL THROMBOSIS (1987) (1)
Fluorescence studies of recombinant plasminogen-activator inhibitor-1 (rpai-1) (1990) (1)
Muscle Cell Proliferation and Neointima Formation After Balloon Injury in Rats Human Endothelial Nitric Oxide Synthase Gene Transfer Inhibits Vascular Smooth (1998) (1)
[Tissue plasminogen activator: a new thrombolytic specific t fibrin]. (1985) (1)
Biochemical principles of fibrinolytic therapy (1981) (1)
Characterisation of rt-PA I276G, a recombinant human tissue-type plasminogen activator mutant with altered plasmin cleavage site (1992) (1)
Measurement of plasmin-antiplasmin complex in plasma: a comparison of latex agglutination, latex agglutination inhibition and hemagglutination inhibition tests. (1978) (1)
The effect of retraction on the clot sensitivity to lysis (1990) (1)
Decreased Reactivity of Plasmin-Streptokinase Towards α-2-Antiplasmin (1979) (1)
Thrombolytic Profiles of Clot-Targeted Plasminogen Activators (2005) (1)
Inhibition of platelet activation by pulmonary nitric oxide reduces vascular response to injury (1997) (1)
A novel role for VEGF-B in motorneuron degeneration in ALS (2005) (1)
Induction of t-pa synthesis with single intravenous bolus injection of a water-miscible vitamin-a preparation in rats and baboons (1991) (1)
Heparin-Binding Domain of Antithrombin Life-Threatening Thrombosis in Mice With Targeted Arg 48-to-Cys Mutation of the Print (2003) (1)
Thrombolytic properties of natural (STAN) and recombinant (STAR) staphylokinase (1992) (1)
Fibrinolytic properties of staphylokinase mutants obtained by ‘clustered charge-to-alanine’ mutagenesis* (1996) (1)
Stent-induced neointima formation and plasminogen activator inhibitor-1 gene transfer in rat carotid arteries (1998) (1)
BIOCHEMICAL AND BIOLOGICAL CHARACTERIZATION OF A NOVEL LOW-MOLECULAR-WEIGHT FORM OF SINGLE CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (SCU-PA) (1986) (1)
Gelatinase activities in mice with targeted inactivation of plasminogen (1997) (1)
Complete inhibition of cardiac wound healing after myocardial infarction in plasminogen deficient mice (1998) (1)
Role of Endothelial versus Smooth Muscle Cells in Blood Vessel Formation (1998) (1)
Adjuvant agents to enhance and sustain reperfusion with t-PA : studies in experimental dog models (1991) (1)
Fibrin-specific Clot Lysis with Single Chain Urokinase-type Plasminogen Activator (scu-PA) (1990) (1)
Biological Properties of Recombinant and of Natural Pro-Urokinase-Reply (1985) (1)
Current clinical experience with staphylokinase in arterial thrombosis (2004) (1)
New thrombolytic strategies and agents (2000) (1)
413. Functional Differences of the Reticuloendothelial System in C57BL/6 and Balb/c Mice Mediate Differential Effects of Kuppfer Cell Blockade, Rag-Deficiency and Splenectomy on Transgene Expression after Adenoviral Transfer (2005) (1)
Potential for Thrombolytic Therapy (1981) (1)
120. Transient Saturation of the Reticuloendothelial System by Non-Cytotoxic Liposomes Increases Hepatocyte Transduction After Adenoviral Gene Transfer (2004) (1)
Amidolytic determination of Factor X in clinical plasma samples. (1983) (1)
Infarct size reduction and recovery of systolic function following coronary thrombolysis (tissue-type plasminogen activator) combined with bWta adrenergic blockade (metoprolol) (1987) (1)
On the origin of the Aalpha chain heterogeneity of human fibrinogen. (1977) (1)
Does Human Protein C Exert Profibrinolytic Activity (1985) (1)
Enhanced fibrinolytic potential in mice with comined homozygous deficiency of alpha2-antiplasmin and plasminogen activator inhibitor-1 (2001) (1)
Plasminogen turnover and plasmin-antiplasmin complex formation in clinical conditions with primary or secondary activation of the fibrinolytic system (1977) (1)
Comparison of recombinant adenovirus vectors expressing antimigratory and antiproliferative proteins in a porcine coronary restenosis model (1998) (1)
New strategies in the development of thrombolytic agents (1988) (1)
Interactions between heparin and fibrinolysis (1994) (1)
77 Role of the ARG123-TYR166 paired helix of APO A-I in lecithin:cholesterol acyltransferase activation (1997) (1)
Plasminogen activator (PA) and matrix metalloproteinase (MMP) system function after vascular injury in mice with targeted inactivation of fibrinolytic genes (1997) (1)
Chromogenic substrate assays of components of the fibrinolytic system. (1982) (1)
Coagulation inhibitor values in myocardial infarction compared to those in normals (1991) (1)
Thyroid hormone inhibits transcription of the human tissue-type plasminogen activator gene promoter (1999) (1)
Intracoronary mesenchymal stem cell or endothelial progenitor cell transfer post myocardial infarction prevents negative remodeling but fails to enhance global functional recovery (2006) (1)
Sustained expression of human apo A-I in 3 different mouse strains (2000) (1)
[Molecular mechanisms of thrombolytic therapy]. (1986) (1)
Modulation of the expression of matrix metalloproteinases and their tissue inhibitors in adipose tissue (2001) (1)
Critical Amplification by Gas6 of the Epo-Dependent Erythropoietic Response to Anemia: Novel Opportunities for Anemia Treatment. (2004) (1)
Regulation of fibrinolysis - recent developments. (1981) (1)
The pathophysiological role of fibrinolysis inhibitors (1984) (1)
Pathophysiology of fibrinolysis (1994) (0)
Hypoxic pulmonary-hypertension in transgenic mice with loss of plasminogen-activator and plasminogen-activator inhibitor gene-function (1995) (0)
AN ALANINE INSERTION IN ALPHA-2-ANTIPLASMIN ENSCHEDE ABOLISHES ITS PLASMIN INHIBITORY ACTIVITY (1987) (0)
Welcome Address by Prof. A. Serradimigni (1986) (0)
Invivo Stimulation of Blood Fibrinolytic-activity By Cp 2129 Al (1983) (0)
GENERAL DISCUSSION AND CONCLUSIONS (1974) (0)
In Memoriam: Burton E. Sobel A Tribute from Family, Friends and Colleagues October 21, 1937 – May 3, 2013 (2013) (0)
29 Urokinase plasminogen activator promotes keratinocyte proliferation in vivo (1997) (0)
Recombinant mutants of fibrinolytic agents (1992) (0)
Physical exercise and fibrinolysis (1990) (0)
Tissue-type plasminogen activator: biochemical considerations and first clinical results (1988) (0)
Evidence for a Functionally Important Plasmin in Inhibitor in Human Plasma, Different from α2-Macroblobulin, α1-Antitrypsin and Antithrombin III (1975) (0)
Thrombosis and thrombolysis (1992) (0)
Thrombolyic properties of a chimeric (t-PA/u-PA) plasminogen activator in a combined arterial and venous thrombosis model in dogs (1991) (0)
Impairment of Fibrinolysis as a Risk Factor for Thrombosis (1984) (0)
Bovine Hageman Factor: Physicochemical Properties and Mechanism of Activation (1975) (0)
Production of spontaneously active plasminogen-activator inhibitor-1 from transfected chinese-hamster ovary cells (1991) (0)
Abstract 1029: Stromelysin-1 is Critical For Intracranial Bleeding After Tissue-type plasminogen activator Treatment Of Stroke In Mice (2007) (0)
Plasminogen Activator Inhibitor-1 Nutritionally Induced Obesity Is Attenuated in Transgenic Mice Overexpressing (2002) (0)
AN ALANINE INSERTION IN α2-ANTIPLASMIN ‘ENSCHEDE’ ABOLISHES ITS PLASM IN INHIBITORY ACTIVITY (1987) (0)
New thrombolytic agents in acute myocardial infarction (1989) (0)
Synergism ofthrombolytic agents: investigational procedures andclinical potential (1988) (0)
Fibrinolytic therapy: future directions (1991) (0)
Lipoproteins and fibrinolysis (1992) (0)
Experience with Marketed Biotech Products: rt-PA (1990) (0)
Subject Index, Vol. 16, Supplement 3, 1986 (1986) (0)
Collen on Cerebral Ischemic Infarction and Pulmonary Clot Lysis in Hamster Models Comparative Effects of Tissue Plasminogen Activator , Streptokinase , and Staphylokinase (1999) (0)
Modulation of tumor metastasis by adenoviral mediated gene transfer of human plasminogen activator inhibitors (1997) (0)
Analysis ofcoagulation andfibrinolysis during intravenous infusion ofrecombinant human tissue-type plasminogen activator inpatients with acutemyocardial infarction* (1986) (0)
Biochemical and preclinical studies on improved thrombolytic therapy. Research contributions during the period 1986-1990. (1992) (0)
Inhibition of experimental venous thrombosis with a human anti-factor VIII monoclonal antibody (2002) (0)
Report of the Meeting of the Subcommittee on Fibrinolysis, San Diego, CA, USA, July 13, 1985 (1985) (0)
New generation of lytic agents (1989) (0)
Structure-function relationships in staphylokinase as revealed by “clusteredcharge-to-alanine” mutagenesis (1994) (0)
Fibrinolytic potency of chimeric plasminogen activators consisting of a single-chain Fv fragment from a fibrin specific antibody (MA-15C5) and of single-chain urokinase (scu-PA) (1992) (0)
Role of urokinase-type plasminogen activator from bone marrow cells in the resolution of venous thrombi (2002) (0)
Left ventricular function and coronary patency 3 months after intravenous tissue-type plasminogen activator treatment in patients with acute myocardial infarction (1987) (0)
On the Mechanism of Action of α2-Antiplasmin (1979) (0)
Erythrocyte-Rich Versus Platelet-Rich Thrombus (2005) (0)
Coronary thrombolysis withrecombinant single- chain urokinase-type plasminogen activator in patients withacutemyocardial infarction (1986) (0)
[Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator]. (1988) (0)
Coronary artery and femoral venous thrombolysis with infusion or bolus recombinant single chain urokinase (saruplase) in dogs (1990) (0)
Natural inhibitors of fibrinolysis (1980) (0)
Title Page / Table of Contents, Vol. 26, Supplement 4, 1996 (1996) (0)
Interactions between stromelsyn-1 (MMP-3) and the plasminogen/urokinase-type plasminogen activator (u-PA) system (1998) (0)
therapeutic potential? Staphylokinase, a fibrin-specific plasminogen activator with (2011) (0)
platelet-rich femoral vein thrombosis model hamster N-(mercaptoacetyl)-D-Tyr-Arg- Gly-Asp-sulfoxide (G4120) in a Antithrombotic properties of L-cysteine, (2011) (0)
18 Role of Sp1 and Sp3 in basal and hormone-induced transcriptional activity of the human t-PA gene promoter (1997) (0)
Correlation between biochemical and biological properties of thrombolytic agents (1990) (0)
Progress in the pharmacology of thrombolytic agents (1992) (0)
insulin and acute-phase response Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma (2011) (0)
A pilot study on thrombolysis with recombinant staphylokinase (star) in patients with peripheral arterial occlusion (1994) (0)
Enhancement by Activated Protein C of tPA-induced Lysis in a Cell-free System (1987) (0)
Effect of ridogrel on the lysis of platelet-rich coronary artery thrombi with recombinant tissue-type plasminogen activator in a canine model (1990) (0)
Pharmacology of fibrinolytic agents (2006) (0)
Tissue-type plasminogen activator as a new thrombolytic agent (1986) (0)
Thrombus Imaging With I-123 Labeled F(ab2) Fragment of a Murine Monoclonal-antibody Specific for Human Fibrin Fragment D-dimer in a Rabbit Model of Venous Thrombosis (1988) (0)
Physiology of fibrinolysis and its role in thrombolysis (1986) (0)
THROMBOLYSIS Synergism of thrombolytic agents in vivo (2005) (0)
plasma clot lysis with single-chain urokinase-type plasminogen activator in plasminogen activator. Application to the study of the mechanism of A monoclonal antibody specific for two-chain urokinase-type (2011) (0)
Pharmacokinetic and thromboyltic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment derived from a fibrin specific antibody (MA-15C5) and single-chain urokinase (scu-PA) (1992) (0)
In Vivo Models For Experimental Thrombolysis (1993) (0)
A BISPECIFIC MONOCLONAL-ANTIBODY AGAINST HUMAN FIBRIN AND AGAINST UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (U-PA) ENHANCES CLOT LYSIS BY U-PA IN ANIMAL-MODELS OF VENOUS THROMBOSIS (1991) (0)
Conformational Alterations of α2-Antiplasmin Induced by Complex Formation with Plasmin (1979) (0)
Fibrinolytic Potential Without Overt Bleeding alpha 2-Antiplasmin Gene Deficiency in Mice Is Associated With Enhanced (2009) (0)
Interrelations between the matrix metalloproteinase and fibrinolytic systems (1999) (0)
Unresolved issues after the available comparative trials of thrombolytic agents in acute myocardial infarction. (1993) (0)
Conformational studies of recombinant plasminogen-activator inhibitor (rpai-1) (1991) (0)
Contributions of biotechnology to thrombolytic therapy (1992) (0)
Biochemical, Thrombolytic and Pharmacokinetic Properties of rt-PA P47G, K49N, a Substitution Variant of Human Tissue-Type Plasminogen Activator (1992) (0)
Hydrostatic pressure and reversible polymerization of fibrin monomers. (2009) (0)
Fibrin-specific thrombolytic agents. (1988) (0)
CHARACTERIZATION OFα2-ANTIPLASMIN.REACTIVE SITE VARIANTS PRODUCED BY SITE-DIRECTED MUTAGENESIS (1987) (0)
Fibrin-selective thrombolytic therapy with staphylokinase (1997) (0)
New generation of thrombolytic agents (1994) (0)
A fully functional deletion staphylokinase derivative crystallizes in two non-isomorphous monoclinic modifications. (1999) (0)
The bleeding-time prolongation induced by the combination of rt-pa and aspirin in rabbits is reversed by reactivated recombinant pai-1 (1989) (0)
mutant resistant to plasminogen activator inhibitor-1 recombinant human tissue-type plasminogen activator deletion Biochemical and biologic properties of rt-PA del ( K 296-G 302 ) (2003) (0)
Key references on thrombolytic therapy 1983-1993. (1994) (0)
Coronary thrombolysis with tissue-type plasminogen activator: prospective review. (1984) (0)
86 Reduction of tumor cell migration and metastasis by plasminogen activator inhibitor gene transfer (1997) (0)
FIBRINOLYTIC RESPONSE TO VENOUS OCCLUSION, AND FIBRIN FRAGMENT D-DIMER AND FIBRONECTIN LEVELS IN NORMAL AND COMPLICATED PREGNANCY (1987) (0)
combinations in venous thrombosis models in dogs and rabbits single-chain urokinase-type plasminogen activator, and synergistic Thrombolytic properties of human tissue-type plasminogen activator, (2013) (0)
Use of staphylokinase for the preparation of a composition for the treatment of vascular thrombosis (1991) (0)
Turnover And Anticoagulant Properties Of Heparin-Antithrombin III Complexes, Stabilized By Covalent Bonds (1981) (0)
polyethylene glycol derivatives of staphylokinase Pharmacokinetic and thrombolytic properties of cysteine-linked (2010) (0)
On the lmmunogenicity of Recombinant Staphylokinase (2018) (0)
Genetically engineered new thrombolytic agents (1995) (0)
Tissue-type plasminogen activator: properties and mechanism of action (1984) (0)
[Tissue plasminogen activator, a new specific thrombolytic of fibrin. Molecular mechanisms and clinical application]. (1985) (0)
Recent progress in blood coagulation and fibrinolysis : proceedings of the International Symposium 'Clot Formation and Lysis' held on March 21-22, 1997, Hamamatsu, Japan, as a satellite symposium of the 74th Annual Meeting of the Japanese Society of Physiology (1997) (0)
Tissue-Type Plasminogen Activator (tPA) (2001) (0)
Differential expression of plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor alpha (TNF-alpha), TNF-alpha converting enzyme and ADAMTS family members in murine fat territories (2002) (0)
Strategies to improve thrombolytic treatment of acute myocardial infarction (1991) (0)
Brief Rapid Communication Coronary Thrombolysis With Recombinant Staphylokinase in Patients With Evolving Myocardial Infarction (2005) (0)
Use of VEGF 165 and homologs for treating neuronal diseases (2001) (0)
Adenoviral human apo A-I gene transfer in apo E-/- mice induces elevation in two lipoprotein-associated anti-inflammatory enzymes, PAF-acetylhydrolase and paraoxonase (1998) (0)
The use of antibodies against the placental growth factor as a new therapeutic target in the pathophysiology of portal hypertensive mice (2008) (0)
Cytochrone P450 epoxygenase inhibition attenuates hypoxia-induced pulmonary vasoconstriction and vascular remodeling in mice (2005) (0)
Mice deficient in growth arrest specific gene 6 (Gas6) show increased hemorrhage in atherosclerosis, myocardial infarction and after LPS-footpad injection and exhibit increased VEGF induced capillary hyperpermeability (2003) (0)
Comparative effects of microplasmin and tPA on ischemic brain damage, neurological function and cerebral hemorrhage in a middle cerebral artery occlusion (MCAO) model (2004) (0)
Characterization of hybrid molecules between tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA) (1988) (0)
[Mechanism of action of heparin]. (1986) (0)
Terzic A and Nelson TJ Regenerative Medicine editorial to Dubois C and Arminan A JACC 2010 (2013) (0)
Implication of stromelysin-1 in the pathophysiology of murine white adipose tissue (2002) (0)
The use of antibodies against the placental growth factor in the prophylactic and therapeutic setting in portal hypertensive mice (2008) (0)
Soluble guanylate cyclase is essential for the pulmonary but not the systemic vasodilator response to NO and increases the pulmonary vascular remodeling response to chronic hypoxia (2006) (0)
Rapid Publication Generation and Characterization of Urokinase Receptor-deficient Mice (1996) (0)
erratum Perinuclear localizationof chromatin facilitates transcriptional silencing (0)
Comparison of local delivery catheters for intracoronary gene transfer in pigs (1998) (0)
Cytochrome Inhibition of P450 epoxygenase attenuates hypoxia-induced pulmonary vasoconstriction and vascular remodeling in mice (2006) (0)
A unique response of human cerebral microvascular endothelial cells to α-thrombin (1994) (0)
[Tissue-type Plasminogen-activator, a New Fibrin-specific Thrombolytic Agent - Molecular Mechanisms and Clinical-application] (1985) (0)
Retracted human clots are more sensititve to lysis with "fibrin-specific" than with "non-fibrin-specific" plasminogen activators (1990) (0)
Pseudo-claudicatio intermittens (1970) (0)
VEGF is a modifier gene of amyotrophic lateral sclerosis in humans (2003) (0)
Ischemia- and cytokine-mediated, mobilization and proliferation of hematopoietic and endothelial stem/progenitor cells require placental growth factor (PlGF) (2003) (0)
142 PLGF Expression By Tumor Stromal Cells Is Induced Via Tumor Cell-Tumor Stromal Crosstalk and Substantially Contributes to Tumor Growth (2008) (0)
THERAPY AND PREVENTION (2005) (0)
3.P.165 Adhesion of monocytes in a coculture model of the arterial wall. Influence of LDL and LPC (1997) (0)
Effects of disruption of genes encoding the plasminogen/plasmin system on vascular neointimal formation in mice (1997) (0)
Antigen binding site glycosylation determines the antiboagulant activity of a Type II Factor VIII antibody withouth modifying affinity or epitope specificity (2005) (0)
Stable expression of human apo A-I for 6 months after transfer with a helper-virus independent adenoviral vector in C57BL/6 mice (2002) (0)
Using VEGF165 and counterparts to treat neuron disorders. (2001) (0)
Clinical Trial Prevention of Coronary Artery Reocclusion and Reduction in Late Coronary Artery Stenosis After Thrombolytic Therapy in Patients With Acute Myocardial Infarction A Randomized Study of Maintenance Infusion of Recombinant Human Tissue-Type Plasminogen Activator (2005) (0)
Nitric Oxide and Apoptosis in Heart Failure (2002) (0)
Discovery and development of a human monoclonal antibody to factor VIII as a new antithrombotic biopharmaceutical (2005) (0)
Paradoxical increase of plaque growth and collagen deposition in atherosclerotic mice lacking plasminogen activator inhibitor-1 (PAI-1) (2000) (0)
FEASIBILITY STUDY OF A LIQUID FORMULATION OF RECOMBINANT STAPHYLOKINASE FOR CORONARY ARTERY THROMBOLYSIS (1998) (0)
5 The multi-hormone responsive enhancer located far upstream from the human tissue-type plasminogen activator gene confers induction by vitamin D (1997) (0)
Novel roles of plasmin, uPAR and suPAR in mobilization and retention of HSC/HPCs (2005) (0)
Vascular and cellular proteolytic activity in mice with α2-antiplasmin gene inactivation (2000) (0)
Protease activity of tissue-type plasminogen activator plays a key role on intracranial bleeding in a middle cerebral artery occlusion model in mice (2008) (0)
The immunochemical determination of thrombin-antithrombin III and plasmin-antiplasmin complexes in human plasma. (1979) (0)
Characterization of a new transcription factor involved in human PAI-1 gene expression (1994) (0)
in a hamster pulmonary embolism model continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator Comparative thrombolytic properties of bolus injections and (2011) (0)
Protease inhibitors : proceedings of the Second International Conference on Fibrinolysis, Hamamatsu, Japan, 26 August 1989 (1990) (0)
PEGylation of vectors in combination with pre-treatment with methylprednisolone inhibits innate immune responses and thrombocytopenia after adenoviral gene transfer (2002) (0)
ROLE OF THE FIBRINOLYTIC AND THE COAGULATION SYSTEM IN THE FORMATION AND DISORDERS OF BLOOD VESSELS (1998) (0)
Enhancement of the thrombolytic potency of single chain urokinase-type plasminogen activator by conjugation with a monoclonal antibody against polymerized fibrin (1991) (0)
Induction of substrate properties in plasminogen-activator inhibitor-1 by point mutations in the active-site loop (1993) (0)
Subjects Index, Vol. 26, Supplement 4, 1996 (1996) (0)
Coronary thrombolysis with tissue-type plasminogen activator (t-PA) (1985) (0)
Recombinant human apo A-I adenoviruses lack hepatotropism after systemic injection in rabbits (1999) (0)
FORTHCOMING ARTICLES IN THE JANUARY ISSUE (2006) (0)
142 Lack of aneurysm formation in atherosclerotic aorta from plasminogen activator deficient mice due to reduced metalloproteinase activity (1997) (0)
human tissue-type plasminogen activator in rabbits Pharmacokinetics and thrombolytic properties of deletion mutants of (2011) (0)
Episomal instability and not cellular immune responses against viral epitopes is the determinant of transgene DNA kinetics in the liver after adenoviral gene transfer (2002) (0)
Size of sinusoidal fenestrae may be a limitation for efficient transduction of hepatocytes in rabbits after adenoviral gene transfer (2003) (0)
Thrombolysis withHumanExtrinsic (Tissue- Type)Plasminogen Activator inRabbits with Experimental Jugular VeinThrombosis (1983) (0)
Hepatic levels of TNF-α, but not of IL-2 and IFN-γ correlate with DNA turnover and hepatoxicity after adenoviral apo A-I transfer (2000) (0)
145 Use of adenoviral vectors to increase reverse cholesterol transport (1997) (0)
A monoclonal anti-PlGF antibody inhibits tumor growth and lymphatic metastasis without affecting healthy vessels (2007) (0)
Plasminogen activator (PA) deficient mice reveal that plasmin is abundant in the ovary prior to ovulation and required for efficient physiological ovulation (1996) (0)
BIOCHEMICAL AND THROMBOLYTIC PROPERTIES OF A PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) RESISTANT VARIANT OF HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR (T-PA) (1991) (0)
Homogeneous myocardial expression of human constitutive nitric-oxide synthase by adenoviral gene-transfer during syngeneic heterotopic heart-transplantation (1995) (0)
Synergism ofthrombolytic agents invivo (2011) (0)
Overexpression of a constitutively-active cGMP-independent protein kinase mutant reduces neointima formation following balloon-injury in rat carotid arteries via an antiproliferative and antimigratory effect (1999) (0)
Inhibition of chronic hypoxic pulmonary hypertension by nitric oxide synthase aerosol gene transfer (1998) (0)
Catheter-Mediated Delivery of Recombinant Adenovirus to the Vessel Wall to Inhibit Restenosis (1999) (0)
Intramolecular domain-domain interactions in tPA and tPA/Uk chimeric molecules (1994) (0)
Cloning and humanization of a cross-linked human fibrin-specific monoclonal antibody (1990) (0)
PlGF (placenta growth factor) stimulates post-ischemic collateral vessel growth with increased perfusion and functional recovery (2002) (0)
Role of the VEGF-isoforms in retinal angiogenesis using transgenic mice that exclusively express one of the VEGF "splice vaiants" (2001) (0)
[Forms of cooperation between industry and university]. (1992) (0)
Diagnostic value of plasma levels of oxidized LDL and of MDA-modified LDL in the assessment of stable angina and of acute coronary syndromes (1998) (0)
Authors Index, Vol. 26, Supplement 4, 1996 (1996) (0)
Enhanced fibrinolytic capacity of alpha2-antiplasmin-deficient mice (1998) (0)
[Tissue plasminogen activator: mechanism of action and thrombolytic properties]. (1984) (0)
The physiology of fibrinolysis (1990) (0)
Effect of the apo E enhancer on human apo A-I expression after adenoviral gene transfer with constructs containing the CMV promoter and human apo A-I promoter or containing only the human apo A-I promoter (1998) (0)
Persistence of human apo A-I expression after adenoviral gene transfer with apo A-I promoter driven constructs (1999) (0)
NEW CONCEPT OF DECREASED THROMBOLYSIS RELATED TO AN ABNORMAL CLOT STRUCTURE (1984) (0)
Cytochrome P450 epoxygenase inhibition attenuates hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling (2005) (0)
Purification and partial primary structure of cyanogen bromide fragments from human alpha 2-antiplasmin. (1982) (0)
Divergent effect of modulation of innate immunity after adenoviral gene transfer in C57BL/6 and Balb/c mice (2003) (0)
A Multicenter Evaluation of an Activated Partial Thromboplastin Time Test, Cepho-Test (1977) (0)
Microplasmin reduces ischemic brain damage and improves neurological function in a rat stroke model monitored with magnetic resonance imaging monitoring (2005) (0)
Relationship between lysine-binding and fibrin-affinity in t-PA and t-PA/u-PA chimeras (1990) (0)
Remodeling of Advanced Atherosclerotic Plaques in Apolipoprotein E Lack of Plasminogen Activator Inhibitor-1 Promotes Growth and Abnormal Matrix (2002) (0)
Physiological consequences of loss of plasminogen gene function (1995) (0)
Negative Selection of a Phage-Displayed Epitopes of Staphylokinase in Humans Using High Resolution Mapping of the B Cell (1998) (0)
Effect of the presence of introns, viral dose, and genetic background on long-term expression of human apo A-I after adenoviral gene transfer (1998) (0)
Differential sensitivity of platelet-rich human plasma clots to staphylokinase (STA) and streptokinase (SK) (1992) (0)
563. Determinants of a Humoral Immune Response Against the Transgene Product after Adenoviral Gene Transfer (2004) (0)
Use of inhibitors of the placental growth factors for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and / or vascular permeability (edema) (2001) (0)
Generation of mice with mutagenized u-pa genes, via the cre/lox recombination strategy (1996) (0)
Detection and determination of disease stages coronary artery. (1999) (0)
Gas6: an orchestrator of platelet-endothelial-leukocyte cell interactions during hemostasis and inflammation (2006) (0)
Recent advances in thrombolytic therapy (1998) (0)
Inhibtion of fibrinolysis: mechanism and clinical implications (1984) (0)
Use of compounds that reduce alfas2-antiplasmins in vivo for preparing a composition for the treatment of ischemic stroke. (1999) (0)
Study of the mechanism of thrombolysis by single chain urokinase-type plasminogen-activator (scu-pa) using a monoclonal-antibody specific for 2-chain urokinase (1989) (0)
Adenovirus-mediated gene transfer of human PAF-AH prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apoE-deficient mice (2001) (0)
Anti-adenoviral immunity and cardiac gene transfer (2002) (0)
Treatment of an aggressive form of motor neuron degeneration by VEGF protein and gene transfer in ALS animal models (2004) (0)
Genetic and chemico-genetic lymph/angiogenesis studies in tadpoles, zebrafish and mice (2006) (0)
Inhibition of Fibrinolysis, Associated with Oncogenic Transformation, by Normal and Antiplasmin-Depleted Human Plasma (1977) (0)
Reduction of in-stent restenosis by adenoviral-mediated NOS3 gene transfer in porcine coronary arteries (1998) (0)
Potent suppression of innate immune responses after adenoviral gene transfer in mice (2002) (0)
VEGF may induce axonal sprouting and preserve neuromuscular junction integrity in vivo (2006) (0)
Genetic insights on the role of PIGF in ocular angiogenesis and inflammation (2010) (0)
A monoclonal antibody against murine PlGF blocks primary tumor growth in syngeneic mouse tumor models (2005) (0)
Thrombolytic properties of chimeric proteins consisting of domains of scu-PA and t-PA and of chemical conjugates of scu-PA with monoclonal anti-fibrin antibody (1989) (0)
Abstract LB-362: PlGF inhibition phenocopies PlGF deficiency in cancer (2010) (0)
Reocclusion and Reduction in Late Coronary Artery Stenosis After Thrombolytic Therapy (2005) (0)
Overexpression of PAI-1 Does Not Affect Adipose Tissue Development in Mice on SFD (2002) (0)
Elevation of HDL cholesterol induced by rabbit apo A-I or rabbit LCAT gene transfer reduces media thinning in a rabbit model of advanced atherosclerosis (2005) (0)
Reactivation of latent plasminogen-activator inhibitor-1 (pai-1) invivo (1990) (0)
Hepatocyte-specific ATP-binding cassette transporter Al gene transfer increases HDL cholesterol but accelerates progression of atherosclerosis in apo E-/- mice (2006) (0)
Fibrin(ogen) degradation by a 24k-endopeptidase from a Chryseobacterium Sp. (2000) (0)
Coronary thrombolysis by intravenous infusion of synergistic thrombolytic agents (1989) (0)
TISSUE PLASMINOGEN ACTIVATOR INHIBITS THROMBIN-INDUCED AGGREGATION AND SHAPE CHANGE,BUT FACILITATES SECRETION,IN GEL-FILTERED PLATELETS ONLY (1987) (0)
[Extrinsic plasminogen activator: molecular properties and potential value as a new thrombolytic agent]. (1982) (0)
Functional role of the oxygen sensors PHD1, PHD2 and PHD3: a gene-inactivation study in mice (2006) (0)
Vascular smooth muscle cell apoptosis in atherosclerotic plaques is mediated by plasminogen activation (2004) (0)
Dual platelet thromboxane-a2 synthase inhibition endoperoxide receptor blockade enhances the lysis of platelet-rich thrombi resistant to rt-pa in canine coronaries (1990) (0)
Use of VEGF and homologs for treating neurological disorders (2001) (0)
Blood flow deficits due to perivascular nerve degeneration: a novel mechanism of ALS (2005) (0)
Gene transfer by adenoviral vectors in rabbit liver depends on the size of endothelial fenestrae (2004) (0)
Generation of mice with inactivated or mutagenized urokinase receptor genes (1995) (0)
Converging evidence for a critical role of the diameter of sinusoidal fenestrae in hepatocyte transduction after adenoviral gene transfer (2007) (0)
Gas6, a novel protein of hemostasis (2002) (0)
Regional myocardial nitric oxide synthase 3 gene transfer reduces tissue-specific consequences of anti adenoviral immune response (2001) (0)
Impact of LDL lowering gene transfer on tissue cholesterol levels in LDL receptor deficient mice (2007) (0)
Cp2129al, a New Fibrinolysis-stimulating Agent (1983) (0)
Utilization growth factor for preventing or treating ischemic heart diseases or cardiovascular events. (2001) (0)
Use of PLGF for the prevention or treatment of ischemia or stroke (2001) (0)
Use of VEGF and homologs for treatment of neuronal diseases (2001) (0)
Lack of aneurysm formation in atherosclerotic aorta from urokinase deficient mice (1997) (0)
Pharmacological modulation of the size of sinusoidal fenestrae is required for efficient transduction of hepatocytes by adenoviral vectors in New Zealand White rabbits (2004) (0)
[Low molecular weight heparin CY 222 (Choay) potentiates the thrombolytic effect of 1-PA in rabbits with experimental thrombosis of the jugular vein]. (1987) (0)
530. Adenoviral and Hydrodynamic Gene Transfer of Replicating Episomes Result in Stable Transgene Expression after Partial Hepatectomy in Mice (2005) (0)
Staphylokinase: Biochemistry And Pharmacodynamics (1997) (0)
Reduced adipose tissue development in mice with deficiency of type1 tissue inhibitor of matrix metalloproteinases (TIMP-1) (2001) (0)
Role of plasminogen activators and matrix metalloproteinases in matrix degradation (1998) (0)
VEGF inhibitors aggravate ALS, possibly by reducing neural perfusion (2006) (0)
Regulation de la formation des adherences tissulaires (2003) (0)
BIOCHEMISTRY AND FIBRIN SPECIFICITY OF SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (1986) (0)
Adenoviral gene transfer of human constitutive endothelial nitric oxide synthase gene inhibits restenosis after angioplasty in porcine coronary arteries (1997) (0)
Biological Effects of Targeted Gene Inactivation and Gene Transfer of the Coagulation and Fibrinolytic Systems in Mice (1997) (0)
Cytochrome P450 epoxygenase inhibition attenuates hypoxia-induced pulmonary vasoconstriction and vascular remodelling in mice (2005) (0)
Molecular mechanisms of inhibition of fibrinolysis (1992) (0)
New developments in thrombolytic therapy for acute myocar dial infarction (1990) (0)
ID: 235 Microplasmin: a novel, direct-acting thrombolytic for treatment of acute vascular occlusions (2006) (0)
Yeast expression vector and a production method for recombinant protein expression in a yeast cell. (2001) (0)
Direct comparison of hepatocyte-specific expression cassettes after adenoviral transfer and hydrodynamic transfer of plasmids and minicircles in C57BL/6 mice (2007) (0)
Molecular Properties of Bovine Hageman Factor (1977) (0)
Replacement of SERCA2a with the non-muscle SERCA2b isoform in transgenic mice (2000) (0)
Retinal Vascular Permeability Is Regulated by VEGFR1 and VEGFR2 (2006) (0)
Placenta Growth Factor (PlGF) mediates mobilization of monocytes and myeloid progenitors during post-ischemic growth, and is a modulator of myeloid differentiation and activation (2002) (0)
548. Ethanol Increases Transgene Expression in Parenchymal Liver Cells after Adenoviral Transfer in Rabbits (2005) (0)
Study of the role of Arg123-Tyr166 central domain of human apo A-I in lipoprotein association, LCAT induced HDL remodeling and atherosclerosis in transgenic mice (1999) (0)
distinct antiapoptotic functions Three differentially expressed survivin cDNA variants encode proteins with (2013) (0)
UTILISATION DE COMPOSES DE REDUCTION DES α2-ANTIPLASMINES IN-VIVO POUR LA PREPARATION D'UNE COMPOSITION THERAPEUTIQUE CONTRE L'ACCIDENT ISCHEMIQUE CEREBRAL (1999) (0)
The use of placenta growth factor in the prevention or treatment of ischemic diseases or stroke (2001) (0)
Contents, Vol. 16, Supplement 3, 1986 (1986) (0)
1115. Apo A-I and ABCA1 Gene Transfer both Increase HDL Cholesterol but Have Opposing Effects on Progression of Early Atherosclerosis in apo E Deficient Mice (2005) (0)
Cardiomyocyte-restricted endothelial nitric oxide synthase overexpression impairs right ventricular remodeling in transgenic mice exposed to chronic hypoxia (2003) (0)
Thrombosis and fibrinolysis - experimental studies (1993) (0)
Epithelial migration in the mouse cornea: Effect of knockouts of genes in the plasminogen activator plasmin system (1996) (0)
Application of a Rat Stroke Model for Preclinical Evaluation of Anti-Stroke Drugs: Noninvasive Monitoring with Comprehensive Magnetic Resonance Imaging (2005) (0)
Novel Role of Plasmin in Mobilization and of uPAR in Retention of Hematopoietic Stem/Progenitor Cells in the Bone Marrow Niche: Therapeutic Implications. (2004) (0)
The use of antibodies against the placental growth factor in the prophylactic setting in the pathophysiology of portal hypertensive mice (2008) (0)
Urokinase plasminogen activator promotes keratinocyte proliferation in vivo (1998) (0)
Effects of coronary thrombolysis combined with beta blockade on regional wall motion and infarct size in dogs (1987) (0)
[Cardiovascular stem cell research in interactions between the university and industry]. (2003) (0)
Species differences in parenchymal liver cell transduction after adenoviral transfer correlate with the diameter of sinusoidal fenestrae (2005) (0)
History of Discovery The Tissue-Type Plasminogen Activator Story (2009) (0)
Blocking primary tumor growth and metastasis by inhibiting PlGF (2006) (0)
Biochemical and biological properties of a recombinant chimera consisting of amino acids Asn-1 to Lys-12 of α2-antiplasmin (fibrin cross-linking site) and amino aids Leu-4 to Leu-411 of single chain urokinase-type plasminogen activator (1992) (0)
Effect of Cr-2129 Al On Fibrinolytic-activity Invitro (1983) (0)
Impaired transplant atherosclerosis in plasminogen deficient mice (1997) (0)
Response : Evidence that survivin inhibits caspase-3 activity (0)
Biomedical applications of biotechnology (2017) (0)
Long-term follow-up of patients with acute myocardial infarction treated with tissue-type plasminogen activator (1985) (0)
Fibrinolysis: Thrombolytic Agents, Mechanisms, and New Developments (1991) (0)
METHODS OF INVITRO AND INVIVO PLASMINOGEN ACTIVATION (1986) (0)
Xenopus tadpoles: a novel model to study functionally the genetic basis of lymphangiogenesis (2004) (0)
Targeting of single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies (1990) (0)
Effect of clodronate liposomes on parenchymal cell transduction after adenoviral gene transfer in Balb/c mice is mimicked by transient saturation of the reticuloendothelial system by non-cytotoxic liposomes (2004) (0)
3.P.118 Oxidation of LDL, endothelial injury and coronary artery disease (1997) (0)
Cardioselective nitric oxide synthase 3 gene transfer reduces endothelial activation, neutrophil infiltration and infarct size following myocardial ischemia-reperfusion injury in pigs (2003) (0)
Quantitation of thrombin-antithrombin III complex during coagulation of blood (1979) (0)
1P-0210 Effects of endogenous placental growth factor on vascular permeability in pathological conditions (2003) (0)
infusion activator to fibrin: useful to monitor fibrinogen breakdown during t-PA A monoclonal antibody preventing binding of tissue-type plasminogen (2011) (0)
Reduced Capillary Density Hypercholesterolemia in Minipigs Impairs Left Ventricular Response to Stress : (2002) (0)
Cardioselective nitric oxide Synthase 3 gene transfer protects against myocardial ischemia-reperfusion injury in pigs (2003) (0)
Th-W61:8 Human apo A-1 transfer enhances expansive remodeling and intimal angiogenesis in a murine model of transplant vasculopathy (2006) (0)
Evaluation of transgene expression, DNA kinetics and transgene immunology after adenoviral gene transfer in six murine strains (2003) (0)
Molecular Biological Aspects of Fibrinolysis (1979) (0)
Inactivation of the tissue factor gene results in embryonic lethality due to abnormal vasculogenesis (1996) (0)
Platelet recruitment to lesion-prone sites is augmented in hyperlipidemic rabbits - Role of P-selectin and vWF (2000) (0)
Endothelial progenitor cell function in hypoxic pulmonary hypertension (2005) (0)
Abstract 3464: Differential Effects of Progenitor Cell Populations on Myocardial Neovascularization and Left Ventricular Remodeling after Myocardial Infarction (2008) (0)
Molecular basis of thrombolysis (2000) (0)
Activation and inhibition of fibrinolytic enzymes (1983) (0)
Effect of copy number and position of human apo E enhancers on transgene DNA persistence after adenoviral human apo A-I gene transfer in C57BL/6 mice (2001) (0)
Tail regeneration in Xenopus laevis: a novel model to study angio- and lymphangiogenesis (2006) (0)
636. Long Term Elevation of HDL Cholesterol Induced by Rabbit apo A-I or Rabbit LCAT Gene Transfer Inhibits Media Thinning in a Rabbit Model of Advanced Atherosclerosis (2005) (0)
Mo-P3:218 ATP-binding cassette transporter A1 gene transfer increases HDL cholesterol but accelerates progression of atherosclerosis in APO E-/- mice (2006) (0)
atherosclerosis-prone sites in response to hypercholesterolemia Endothelial von Willebrand factor recruits platelets to (2013) (0)
[Reperfusion in acute myocardial infarct. The Working Group in Myocardial Reperfusion. The International Society and Federation of Cardiology (ISFC)]. (1994) (0)
Vascular Endothelial Cell Function and Thrombosis (2007) (0)
Macrophage Accumulation Placental Growth Factor Promotes Atherosclerotic Intimal Thickening and (2005) (0)
Not gelatinase B (MMP9) but stromelysin-1 (MMP3) is critical for intracranial bleeding following tissue-type plasminogen activator (tPA) treatment in a mouse stroke model (2007) (0)
[Clinical significance of the communications between abdominal territories. (Arteria coeliaca, arterial mesentericae superior and inferior)]. (1969) (0)
Blocking primary tumor growth and lymphatic metastases by targeting PlGF (2006) (0)
Intrahepatic distribution of adenoviral vectors is critically dependent on the size of sinusoidal fenestrae (2004) (0)
Genetic and chemico-genetic lymphangiogenesis study of VEGFR-3 and its ligands VEGF-D and VEGF-C in Xenopus laevis tadpoles (2006) (0)
Circulating oxidized LDL and the assessment of cardiovascular risk (2000) (0)
Use of VEGF and homologues to treat neurological disorders (2001) (0)
Human apo A-I gene transfer inhibits restenosis in apo E deficient mice (1996) (0)
Improved therapeutic index of adenoviral vectors for liver-directed gene transfer by PEGylation and premedication with methylprednisolone (2003) (0)

This paper list is powered by the following services:

Other Resources About Désiré Collen

en.wikipedia.org

What Schools Are Affiliated With Désiré Collen?

Désiré Collen is affiliated with the following schools:

Désiré Collen's Academic­Influence.com Rankings

Why Is Désiré Collen Influential?

Désiré Collen's Published Works

Published Works

Other Resources About Désiré Collen

What Schools Are Affiliated With Désiré Collen?

Image Attributions

Désiré Collen's AcademicInfluence.com Rankings